乾癬・掌蹠膿疱症

出版社: 中山書店
著者:
発行日: 2020-09-05
分野: 臨床医学:内科  >  皮膚科
ISBN: 9784521748610
電子書籍版: 2020-09-05 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

14,300 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,300 円(税込)

商品紹介

乾癬はIL-17やIL-23が中心的な役割を果たす疾患として知られ,全身性の炎症性疾患としてとらえられる.
近年登場した生物学的製剤は,難治といわれた部位や症状にも著効し,乾癬の治療を激変させている.
本書は,乾癬に加え,類縁疾患や掌蹠膿疱症も取り上げ,基礎研究から応用まで多角的な視点から最新の知見を紹介する.コラムも豊富で,現時点での乾癬のトレンドがこの1冊で理解できる.

目次

  • 乾癬・掌蹠膿疱症の皮疹

    1章 総論
     1 疾患感受性遺伝子(尋常性乾癬,乾癬性関節炎)
     2 乾癬における自己抗原-最近の話題
     3 爪乾癬
     4 小児の乾癬
     Column superimposed psoriasis(superimposed linear psoriasis)
     5 高齢者の乾癬
     6 アドヒアランス・治療満足度
     7 患者会の現状

    2章 尋常性乾癬
     1 乾癬の疫学
     2 尋常性乾癬の病因・病態の歴史
     Column 乾癬はどの範疇に入る疾患なのか?
     Column 乾癬の表皮と真皮の相互作用
     3 ケラチノサイトからみた乾癬の病態 
     4 自然免疫(抗菌ペプチド,ILC3, γδ)からみた乾癬の病態
     Column 尋常性乾癬とカンジダ 
     5 獲得免疫(Th1/17, Treg)からみた乾癬の病態
     6 血管内皮細胞からみた乾癬の病態
     7 上皮-免疫微小環境(EIME)
     8 乾癬と腫瘍壊死因子α(TNF-α)
     9 乾癬とIL-23/Th17 axis, IL-36
     10 乾癬の動物モデル
     11 乾癬のかゆみ
     12 Kobner 現象,photo-Kobner 現象,Renbok 現象
     Column Renbok 現象
     Column 乾癬の粘膜疹
     13 尋常性乾癬と感染症
     Column 乾癬と悪性腫瘍
     14 乾癬とレジデントメモリーT 細胞
     15 乾癬と喫煙
     16 全身性炎症性疾患
     Column 乾癬と肉芽腫の接点
     Column 乾癬と全身性エリテマトーデス
     Column 乾癬と全身性強皮症
     Column 乾癬と皮膚筋炎
     Column psoriatic disease とpsoriatic march
     17 尋常性乾癬と鑑別すべき疾患
     Column 乾癬と扁平苔癬―相違点と類似点
     18 外用療法
     Column なぜ頭部乾癬は治りにくいか?
     19 光線療法
     20 内服療法
     21 生物学的製剤
     22 クリニックの乾癬治療

    3章 乾癬の特殊型
     1 滴状乾癬
     2 乾癬性紅皮症の病態
     3 seborrheic psoriasis, psoriasis inversa, psoriasis verrucosa
     Column 頭部乾癬と脂漏性皮膚炎をどう鑑別するか?
     4 薬剤性乾癬
     Column 生物学的製剤によるパラドキシカル反応

    4章 乾癬性関節炎
     1 乾癬性関節炎の疫学
     2 乾癬性関節炎の付着部炎
     3 乾癬性関節炎の滑膜炎
     Column 乾癬性関節炎の付着部炎とIL-17,IL-23
     4 乾癬性関節炎の指趾炎
     5 乾癬性関節炎モデルマウス
     Column PsA sine psoriasis
     6 乾癬性関節炎の治療
     7 乾癬性関節炎の併存症
     8 乾癬性関節炎の鑑別診断
     Column 胸肋鎖関節炎と乾癬性関節炎

    5章 膿疱性乾癬
     1 膿疱性乾癬の臨床分類
     Column GPPとAGEPの鑑別
     2 膿疱性乾癬の疫学
     Column 膿疱性乾癬の併存疾患
     3 膿疱性乾癬の病態
     Column 膿疱性乾癬の発症年齢
     Column 疱疹状膿痂疹(乾癬と妊娠)
     4 膿疱性乾癬の治療

    6章 掌蹠膿疱症
     1 掌蹠膿疱症の疫学
     2 掌蹠膿疱症の臨床
     3 掌蹠膿疱症の病態
     Column 掌蹠膿疱症の動物モデル
     4 金属アレルギー
     5 口腔のマイクロバイオーム
     6 皮膚のマイクロバイオーム
     7 掌蹠膿疱症の病理組織
     8 掌蹠膿疱症の鑑別診断
     9 掌蹠膿疱症の併存症-とくに骨関節炎
     10 SAPHO症候群の診断と治療
     Column 慢性再発性多発性骨髄炎(CRMO)とSAPHO症候群
     Column 小児の掌蹠膿疱症,掌蹠膿疱症性骨関節炎
     11 掌蹠膿疱症の治療方針
     12 掌蹠膿疱症の病巣感染-扁桃
     13 掌蹠膿疱症の病巣感染-歯性感染症

    7章 評価法/尺度
     1 乾癬の評価法
     2 乾癬性関節炎の評価法
     3 掌蹠膿疱症の評価法(PPPASI, PPSI)
     4 QOLの評価法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 総論

P.7 掲載の参考文献
2) Farber EM, Nail ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974 ; 148 : 1-18.
3) 小澤明. 乾癬. 疫学・統計. 山村雄一ほか (編). 現代皮膚科学大系 第4巻B 角化異常性疾患 II. 中山書店 ; 1981. pp.3-11.
5) Henseler T, Christophers E. Psoriasis of early and late onset : Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985 ; 13 : 450-6.
6) Lew W, Lee E, Krueger JG. Psoriasis genomics : Analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol 2004 ; 150 : 668-76.
7) Kim J, Oh CH, Jeon J, et al. Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL?17 Pathway Genes but Different Regulatory Gene Sets. J Invest Dermatol 2016 ; 136 : 161-72.
8) Ozawa A, Ohkido M, Tsuji K. Some recent advances in HLA and skin diseases. J Am Acad Dermatol 1981 ; 4 : 205-30.
9) Mabuchi T, Ota T, Manabe Y, et al. HLA-C*12 : 02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol 2014 ; 41 : 697-704.
10) 小澤明. 尋常性乾癬における主要組織適合抗原-II. DR (Drelated) 抗原の解析. 日皮会誌 1978 ; 88 : 981-92.
11) Mabuchi T, Oka A, Iizuka M, et al. Fine mapping of a psoriasis?susceptibility locus within the HLA class II region by using microsatellite markers in an association study of Japanese cases and controls. Tokai J Exp Clin Med 2007 ; 32 : 6-13.
12) Mabuchi T, Hirayama N. Binding Affinity and Interaction of LL-37 with HLA-C*06 : 02 in Psoriasis. J Invest Dermatol 2016 ; 136 : 1901-3.
13) Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T?cell autoantigen in psoriasis. Nat Commun 2014 ; 5 : 5621.
14) Yunusbaeva M, Valiev R, Bilalov F, et al. Psoriasis patients demonstrate HLA-Cw*06 : 02 allele dosage-dependent T cell proliferation when treated with hair follicle?derived keratin 17 protein. Sci Rep 2018 ; 8 : 6098.
15) Arakawa A, Siewert K, Stohr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015 ; 212 : 2203-12.
17) 馬渕智生, 小澤明. 乾癬の疾患遺伝子. 古江増隆, 大槻マミ太郎 (編). 皮膚科臨床アセット 10 ここまでわかった乾癬の病態と治療. 中山書店 ; 2012. pp.6-10.
18) Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994 ; 264 : 1141-5.
19) Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012 ; 90 : 784-95.
20) Riveira-Munoz E, He SM, Escaramis G, et al. Meta-Analysis Confirms the LCE3C_LCE3B Deletion as a Risk Factor for Psoriasis in Several Ethnic Groups and Finds Interaction with HLA-Cw6. J Invest Dermatol 2011 ; 131 : 1105-9.
21) Li K, Huang CC, Randazzo B, et al. HLA-C*06 : 02 Allele and Response to IL-12/23 Inhibition : Results from the Ustekinumab Phase 3 Psoriasis Program. J Invest Dermatol 2016 ; 136 : 2364-71.
22) Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis : SUPREME study. Br J Dermatol 2018 ; 179 : 1072-80.
23) Eder L, Chandran V, Gladman DD. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr Opin Rheumatol 2015 ; 27 : 91-8.
24) FitzGerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis : Genotype determines clinical phenotype. Arthritis Res Ther 2015 ; 17 : 115.
P.14 掲載の参考文献
1) Prinz JC. Autoimmune aspects of psoriasis : Heritability and autoantigens. Autoimmun Rev 2017 ; 16 : 970-9.
2) Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2014 ; 5 : 5621.
3) Arakawa A, Siewert K, Stohr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015 ; 212 : 2203-12.
4) Cheung KL, Jarrett R, Subramaniam S, et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med 2016 ; 213 : 2399-412.
5) Yuan Y, Qiu J, Lin Z-T, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheum 2019 ; 71 : 941-51.
P.20 掲載の参考文献
1) Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis : A questionnaire-based survey. Br J Dermatol 2013 ; 169 : 314-9.
2) Van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. Dermatol Clin 2000 ; 18 : 37-46.
3) Zenke Y, Ohara Y, Kobayashi D, et al. Nail findings in patients with psoriatic arthritis : A cross-sectional study with special reference to transverse grooves. J Am Acad Dermatol 2017 ; 77 : 863-7.
4) Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail : Anatomy, pathology, clinical presentation, and a review of a literature on therapy. J Am Acad Dermatol 2007 ; 57 : 1-27.
5) 齋藤昌孝. 治療に難渋する病態への対応- (1) 爪乾癬の診断から治療まで. 皮膚臨床 2018 ; 60 (10) : 1517-23.
6) Zaias N. Psoriasis of the nail : A clinical-pathologic study. Arch Dermatol 1969 ; 99 : 567-79.
7) Gutierrez M, et al. High-frequency Sonography in the Evaluation of Psoriasis : Nail and Skin Involvement. J Ultrasound Med 2009 ; 28 : 1569-74.
8) Rich P, Scher RK. Nail Psoriasis Severity Index : A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003 ; 49 : 206-12.
9) Augustin M, Blome C, Costanzo A, et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) : Development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol 2014 ; 170 : 591-8.
10) Yamamoto T, Mori T. Epidermal mast cells in the nail matrix of a patient with psoriasis confined to the nails. Clin Exp Dermatol 2018 ; 43 : 460-1.
P.29 掲載の参考文献
1) Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis : A systematic review of incidence and prevalence. J Invest Dermatol 2013 ; 133 (2) : 377-85.
2) Takahashi H, Nakamura K, Kaneko F, et al. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011 ; 38 (12) : 1125-9.
3) Ito T, Takahashi H, Kawada A, et al. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol 2018 ; 45 (3) : 293-301.
4) Burden-Teh E, Thomas KS, Ratib S, et al. The epidemiology of childhood psoriasis : A scoping review. Br J Dermatol 2016 ; 174 (6) : 1242-57.
5) Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis : Evolving perspectives. Pediatr Dermatol 2018 ; 35 (2) : 170-81.
6) Cordoro KM, Hitraya-Low M, Taravati K, et al. Skininfiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol 2017 ; 77 (3) : 417-24.
P.30 掲載の参考文献
1) Happle R. Superimposed segmental manifestation of polygenic skin disrders. J Am Acad Dermatol 2007 ; 57 : 690-9.
P.34 掲載の参考文献
1) 日本の人口と世帯. 2. 高齢化率の推移. GD Freal ; 2019.7.18更新. https://jp.gdfreak.com/public/detail/jp010050000001000000/2
2) 梅澤慶紀, 中川秀己. 高齢者での乾癬治療. 臨床皮膚科 2014 ; 68 (5) : 99-103.
3) Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther 2018 ; 18 (8) : 897-903.
4) 藤田英樹. レチノイドを生かした乾癬治療. MB Derma 2016 ; 240 : 25-32.
5) Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol 2014 ; 41 : 974-80.
6) Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol 2016 ; 41 : 564-6.
7) Tsuda K, Yamanaka K, Kondo M, et al. Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity. PLos One 2012 ; 7 (12) : e51819.
8) Yamanaka K, Umezawa Y, Yamagiwa A, et al. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils. J Dermatol 2014 ; 41 (8) : 679-85.
9) Korber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis : A pooled analysis of phase III studies. Drugs Aging 2018 ; 35 : 135-44.
10) Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016 ; 375 : 345-56.
11) Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016 ; 175 : 273-86.
12) Yamanaka, K, Nakanishi T, Saito H, et al. Persistent release of IL-1s from skin is associated with systemic cardio-vascular disease, emaciation and systemic amyloidosis : The potential of anti-IL-1 therapy for systemic inflammatory diseases. PLoS One 2014 ; 9 (8) : e104479.
13) Yamanaka K, Mizutani H. "Inflammatory skin march" : IL-1-mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events. J Allergy Clin Immunol 2015 ; 136 (3) : 823-4.
P.40 掲載の参考文献
1) 加藤則人, 大矢幸弘, 池田政憲ほか. アトピー性皮膚炎診療ガイドライン 2018. 日皮会誌 2018 ; 128 : 2431-502.
2) 加藤則人, 大矢幸弘, 池田政憲ほか. アトピー性皮膚炎診療ガイドライン 2018. アレルギー 2018 ; 67 : 1297-367.
3) Furue M, Hagihara A, Takeuchi S, et al. Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by Morisky Medication Adherence Scale-8. Br J Dermatol 2015 ; 172 : 272-5.
4) Saeki H, Imafuku S, Abe M, et al. Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients. J Dermatol 2015 ; 42 : 367-72.
5) Ichiyama S, Ito M, Funasaka Y, et al. Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities. J Dermatol 2018 ; 45 : 727-31.
P.47 掲載の参考文献
1) 日本乾癬患者連合会ホームページ. http://jpa1029.com/
2) NPO法人東京乾癬の会 P-PATホームページ. https://www.p-pat.org/
3) International Federation of Psoriasis Associations (IFPA) Home Page. https://ifpa-pso.com
4) International Federation of Psoriasis Associations (IFPA). Giving a global voice to more then 125 million people with psoriasis. http://www.worldpsoriasisday.com/
5) INSPIRE JAPAN WPD乾癬啓発普及協会. 活動報告. http://www.inspirejapan-wpd.net/category/activities/
6) 安部正敏. 患者会活動. 大槻マミ太郎 (編). 皮膚科臨床アセット 10 ここまでわかった乾癬の病態と治療. 中山書店 ; 2012. pp.280-5.

2章 尋常性乾癬

P.54 掲載の参考文献
2) Takahashi H, Nakamura K, Kaneko F, et al ; Japanese Society for Psoriasis Research. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011 ; 38 : 1125-9.
3) Ito T, Takahashi H, Kawada A, et al. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol 2018 ; 45 : 293-301.
4) 照井正, 中川秀己, 江藤隆史ほか. 健康保険組合レセプト情報を利用した乾癬の実態調査. 臨床医薬 2014 ; 30 : 279-85.
5) Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis : A nationwide study using the Japanese national claims database. BMJ Open 2015 ; 5 : e006450.
P.57 掲載の参考文献
1) Kuek A, Hazelman BL, Ostor AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy : A medical revolution. Postgrad Med J 2007 ; 83 : 251-60.
2) Murthy AS, Leslie K. Autoinflammatory skin disease : A review of concepts and applications to general dermatology. Dermatology 2016 ; 232 : 534-40.
3) Wang J, Huang A, Xu W, et al. Insights into IL-29 : Emerging role in inflammatory autoimmune diseases. J Cell Mol Med 2019 ; 23 : 7926-32.
P.60 掲載の参考文献
1) Briggaman RA. Epidermal-dermal interactions in adult skin. J Invest Dermatol 1982 ; 79 : 21s-4s.
2) Dainichi T, Kitoh A, Ohtsuka A, et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis vulgaris. Nat Immunol 2018 ; 19 : 1286-98.
P.62 掲載の参考文献
1) 川田 暁. 乾癬の疫学と治療-最近の知見. 総合臨床 2007 ; 56 : 3285-6.
2) Shuster S. Research into psoriasis : The last decade. Br Med J 1971 ; 24 : 236-9.
3) Zhang L. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis. Front Immunol 2019 ; 10 : 1440.
4) 戸倉新樹. 乾癬発症の引き金としての微生物. 飯塚一ほか (編). 皮膚科診療プラクティス. 乾癬にせまる. 文光堂 ; 2004. pp.56-60.
5) Ozawa A, Ohkido M, Tsuji K. Some recent advances in HLA and skin diseases. J Am Acad Dermatol 1981 ; 4 : 205-30.
6) 飯塚一. 乾癬表皮の細胞周期-細胞周期時間の短縮か? Growth Fractionの増大か? 皮膚 1994 ; 36 : 896-901.
7) Van Scott EJ, Reinerston RP. Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J Invest Dermatol 1959 ; 33 : 357-69.
8) Rothberg S, Crounse RG, Lee JL. Glycine C14 incorporation into proteins of normal stratum corneum and abnormal stratum corneum of psoriasis. J Invest Dermatol 1961 ; 37 : 497-504.
9) Van Scott EJ, Ekel TM. Kinetics of hyperplasia in psoriasis. Arch Dermatol 1963 ; 88 : 373-81.
10) 小宮根真弓. 乾癬の病態理論と治療の変遷. 皮膚病診療 2017 ; 39 : 1236-41.
11) Gubner R, August S, Ginsberg V. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951 ; 221 : 176-82.
12) Edmundson WF, Guy WG. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 1958 ; 78 : 200-3.
13) Ashton RE, Andre P, Lowe N, et al. Anthralin : Historical and current perspectives. J Am Acad Dermatol 1983 ; 9 : 173-92.
14) Goldman L, Thompson RG, Trice ER. Cortisone acetate in skin disease : Local effect in the skin from topical application and local injection. AMA Arch Derm Syphilol 1952 ; 65 : 177-86.
15) Goeckerman WH. The treatment of psoriasis. Northwest Med 1925 ; 24 : 229-31.
16) Parrish JA, Fitzpatrick TB, Tannenbaum L, et al. Photochemotherapy of psoriasis with oral mexhoxsalen and long wave ultraviolet light. N Eng J Med 1974 ; 291 : 1207-11.
17) 水野信行, 大野盛秀, 植松茂生. 尋常性乾癬の8-Methoxypsoralen療法. 日皮会誌 1975 ; 85 : 577-85.
18) Parrish JA, Jaenicke KF. Action spectrum for psoriasis. J Invest Dermatol 1981 ; 76 : 359-62.
19) Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol 1987 ; 16 : 267-91.
20) Morimoto S, Kumahara Y. A patient wth psoriasis cured by 1α-hydroxyvitamin D3. Med J Osaka Univ 1985 ; 35 : 51-4.
21) Voorhees JJ, Duell EA, Bass LJ, et al. Decreased cyclic AMP in the epidermis of lesions of psoriasis. Arch Dermatol 1972 ; 105 : 695-701.
23) 飯塚一. 乾癬治療 温故知新-治療からみた乾癬病態論の変遷. 皮膚臨床 2018 ; 60 : 1459-65.
24) 吉川邦彦. 乾癬とサイクリックAMP-新しい内服治療の誕生. 高知医誌 2019 ; 24 : 62-71.
25) Guihou JJ, Meynadier J, Clot J. New concepts in the pathogenesis of psoriasis. Br J Dermatol 1978 ; 98 : 585-92.
26) Cormane RH. Immunopathology of psoriasis. Arch Dermatol Res 1981 ; 270 : 201-15.
27) Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Eng J Med 1979 ; 301 : 555.
28) 朝比奈昭彦. 乾癬に対するTNF-αアンタゴニスト以外の生物学的製剤による治療. MB Derma 2010 ; 169 : 29-35.
29) Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992 ; 126 : 1-9.
30) Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991 ; 138 : 129-40.
31) Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000 ; 42 : 829-30.
32) Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005 ; 202 : 135-43.
33) Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005 ; 102 : 19057-62.
34) Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis : Current prospects. J Am Acad Dermatol 2007 ; 57 : 1059-68.
35) Cesare AD, Meglio PD, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009 ; 129 : 1339-50.
36) Nestle FO, Meglio PD, Qin J, et al. Skin immune sentinels in health and disease. Nat Rev Immunol 2009 ; 9 : 679-91.
P.69 掲載の参考文献
1) Tomic-Canic M, Komine M, Freedberg IM, et al. Epidermal signal transduction and transcription factor activation in activated keratinocytes. J Dermatol Sci 1998 ; 17 : 167-81.
2) Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013 ; 34 : 174-81.
3) Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018 ; 45 : 264-72.
4) Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 2012 ; 39 : 225-30.
5) Wang M, Zhang S, Zheng G, et al. Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. Immunity 2018 ; 49 : 66-79.
P.74 掲載の参考文献
1) Buchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 2007 ; 25 (6) : 616-24.
2) Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett 1995 ; 368 (1) : 173-6.
3) Sorensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001 ; 97 (12) : 3951-9.
4) Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002 ; 347 (15) : 1151-60.
5) Baker BS, Ovigne JM, Powles AV, et al. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5 : Modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003 ; 148 (4) : 670-9.
6) Kolbinger F, Loesche C, Valentin MA, et al. beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017 ; 139 (3) : 923-32.
7) Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007 ; 449 (7162) : 564-9.
8) Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2014 ; 5 : 5621.
9) Spits H, Artis D, Colonna M, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol. 2013 ; 13 (2) : 145-9.
10) 澤新一郎. 自然リンパ球とは? -機能的特徴に基づいた最新の分類. リンパ学 2015 ; 38 (2) : 84-9.
11) Ebbo M, Crinier A, Vely F, et al. Innate lymphoid cells : Major players in inflammatory diseases. Nat Rev Immunol 2017 ; 17 (11) : 665-78.
12) Villanova F, Flutter B, Tosi I, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol 2014 ; 134 (4) : 984-91.
13) Teunissen MBM, Munneke JM, Bernink JH, et al. Composition of innate lymphoid cell subsets in the human skin : Enrichment of NCR (+) ILC3 in lesional skin and blood of psoriasis patients. J Invest Dermatol 2014 ; 134 (9) : 2351-60.
14) Dyring-Andersen B, Geisler C, Agerbeck C, et al. Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br J Dermatol 2014 ; 170 (3) : 609-16.
15) Pantelyushin S, Haak S, Ingold B, et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J Clin Invest 2012 ; 122 (6) : 2252-6.
16) Keren A, Shemer A, Ginzburg A, et al. Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin. J Allergy Clin Immunol 2018 ; 142 (1) : 305-8.
17) Soare A, Weber S, Maul L, et al. Cutting Edge : Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis. J Immunol 2018 ; 200 (4) : 1249-54.
18) O'Brien R, Jin N, Huang Y, et al. Characteristics of IL-17-producing gammadelta T cells. Immunity 2010 ; 32 (1) : 1 ; author reply 2-4.
19) Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011 ; 35 (4) : 596-610.
20) Laggner U, Di Meglio P, Perera GK, et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J Immunol 2011 ; 187 (5) : 2783-93.
21) Gray EE, Suzuki K, Cyster JG. Cutting edge : Identification of a motile IL-17-producing gammadelta T cell population in the dermis. J Immunol 2011 ; 186 (11) : 6091-5.
P.76 掲載の参考文献
1) Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol 2018 ; 16 : 143-55.
2) Langan EA, Kunstner A, Miodovnik M, et al. Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis. Br J Dermatol 2019 ; 181 : 1254-64.
3) Takemoto A, Cho O, Morohoshi Y, et al. Molecular characterization of the skin fungal microbiome in patients with psoriasis. J Dermatol 2015 ; 42 : 166-70.
4) Hurabielle C, Link VM, Bouladoux N, et al. Immunity to commensal skin fungi promotes psoriasiform skin inflammation. Proc Natl Acad Sci USA 2020 ; 117 : 16465-74.
5) van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009 ; 182 : 5836-45.
P.82 掲載の参考文献
1) Baumgarth N, Bevins Cl. Autoimmune disease : A skin deep but complex. Nature 2007 ; 449 : 551-3.
2) Yoshiki R, Kabashima K, Honda T, et al. IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells. J Invest Dermatol 2014 ; 134 : 1912-21.
3) 多田弥生. BenchとBedsideを行き来するうちにわかってきた乾癬の病態. 皮膚科の臨床 2014 ; 56 : 1141-51.
4) Shimizu T, Kamata M, Fukaya S, et al. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. J Dermatol Sci 2019 ; 95 : 90-8.
5) Hau CS, Shimizu T, Tada Y, et al. The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production. J Dermatol Sci 2018 ; 92 : 117-26.
6) Kubo R, Muramatsu S, Sagawa Y, et al. Bath-PUVA therapy improves impaired resting regulatory T cells and increases activated regulatory T cells in psoriasis. J Dermatol Sci 2017 ; 86 : 46-53.
P.88 掲載の参考文献
1) Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In : Elder DE (ed). Lever's Histopathology of the Skin, 10th edition. Lippincott Williams & Wilkins ; 2009. pp.175-8.
2) Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987 ; 18 (3) : 234-9.
3) Cliff WJ. Blood Vessels. Cambridge University Press ; 1976.
4) Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost 2000 ; 26 (5) : 463-78.
5) Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008 ; 111 (11) : 5271-81.
6) Yano K, Gale D, Massberg S, et al. Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium. Blood 2007 ; 109 (2) : 613-5.
7) 川名誠司. 皮膚の脈管と神経. 富田靖ほか編. 標準皮膚科, 9版. 医学書院 ; 2010. pp.18-9.
8) Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation : Cause or consequence? Angiogenesis 2007 ; 10 (3) : 149-66.
9) Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994 ; 180 (3) : 1141-6.
10) Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003 ; 102 (1) : 161-8.
11) Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008 ; 173 : 265-77.
12) Ehrlich A, Booher S, Becerra Y, et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 2004 ; 50 (4) : 533-40.
13) Espinoza LR, Vasey FB, Espinoza CG, et al. Vascular changes in psoriatic synovium : A light and electron microscopic study. Arthritis Rheum 1982 ; 25 : 677-84.
14) Fearon U, Reece R, Smith J, et al. Synovial cytokine and growth factor regulation of MMPs/TIMPs : Implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann NY Acad Sci 1999 ; 878 : 619-21.
15) Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, et al. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol 2011 ; 164 (1) : 26-32.
16) Abe R, Yamagishi S, Fujita Y, et al. Topical application of anti-angiogenic peptides based on pigment epitheliumderived factor can improve psoriasis. J Dermatol Sci 2010 ; 57 (3) : 183-91.
P.97 掲載の参考文献
1) Dainichi T, Hanakawa S, Kabashima K. Classification of inflammatory skin diseases : A proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity. J Dermatol Sci 2014 ; 76 : 81-9.
2) Dainichi T, Kitoh A, Otsuka A, et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat Immunol 2018 ; 19 : 1286-98.
3) Sandby-Moller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites : Relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm Venereol 2003 ; 83 : 410-3.
4) Furue M, Yamazaki S, Jimbow K, et al. Prevalence of dermatological disorders in Japan : A nationwide, crosssectional, seasonal, multicenter, hospital-based study. J Dermatol 2011 ; 38 : 310-20.
6) Palmer CN, Ismail T, Lee SP, et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007 ; 120 : 64-8.
7) Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol 2012 ; 7 : 385-422.
8) Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NFkappaB, in psoriasis. Am J Hum Genet 2012 ; 90 : 796-808.
10) Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature 2013 ; 503 : 397-401.
11) Loesche MA, Farahi K, Capone K, et al. Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. J Invest Dermatol 2018 ; 138 : 1973-81.
12) Alekseyenko AV, Perez-Perez GI, De Souza A, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013 ; 1 : 31.
13) Gao Z, Tseng CH, Strober BE, et al. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One 2008 ; 3 : e2719.
14) Amaya M, Tajima M, Okubo Y, et al. Molecular analysis of Malassezia microflora in the lesional skin of psoriasis patients. J Dermatol 2007 ; 34 : 619-24.
15) Takemoto A, Cho O, Morohoshi Y, et al. Molecular characterization of the skin fungal microbiome in patients with psoriasis. J Dermatol 2015 ; 42 : 166-70.
16) Tagami H, Yoshikuni K. Interrelationship between waterbarrier and reservoir functions of pathologic stratum corneum. Arch Dermatol 1985 ; 121 : 642-5.
17) Takahashi H, Tsuji H, Minami-Hori M, et al. Defective barrier function accompanied by structural changes of psoriatic stratum corneum. J Dermatol 2014 ; 41 : 144-8.
18) Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 2012 ; 21 : 104-10.
19) Matsumoto R, Dainichi T, Tsuchiya S, et al. Epithelial TRAF6 drives IL-17-mediated psoriatic inflammation. JCI Insight 2018 ; 3 : e121175.
20) Riol-Blanco L, Ordovas-Montanes J, Perro M, et al. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. Nature 2014 ; 510 : 157-61.
21) Kashem SW, Riedl MS, Yao C, et al. Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity. Immunity 2015 ; 43 : 515-26.
22) Cohen JA, Edwards TN, Liu AW, et al. Cutaneous TRPV1 (+) Neurons Trigger Protective Innate Type 17 Anticipatory Immunity. Cell 2019 ; 178 : 919-32.
P.101 掲載の参考文献
1) Tokura Y, Mori T, Hino R. Psoriasis and other Th17-mediated skin diseases. J UOEH 2010 ; 32 : 317-28.
2) Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004 ; 140 : 1490-5.
3) Suzuki T, Hirakawa S, Shimauchi T, et al. VEGF-A promotes IL-17A-producing γδ T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci 2014 ; 74 : 116-24.
P.107 掲載の参考文献
1) Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017 ; 140 : 645-53.
2) de Jong E, Suddason T, Lord GM. Translational mini-review series on Th17 cells : development of mouse and human T helper 17 cells. Clin Exp Immunol 2009 ; 159 : 148-58.
3) 佐藤伸一. T細胞と表皮細胞からみた乾癬の病態. 診療と新薬 2016 ; 53 : 971-9.
4) Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011 ; 12 : 1159-66.
5) Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signaling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol 2018 ; 98 : 5-13.
P.112 掲載の参考文献
1) Wagner EF, Schonthaler HB, Guinea-Viniegra J, et al. Psoriasis : What we have learned from mouse models. Nat Rev Rheumatol 2010 ; 6 (12) : 704-14.
2) Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014 ; 32 : 227-55.
3) Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005 ; 11 (1) : 43-9.
4) Hedrick MN, Lonsdorf AS, Shirakawa AK, et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 2009 ; 119 (8) : 2317-29.
5) Boyman O, Hefti HP, Conrad C, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004 ; 199 (5) : 731-6.
6) van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009 ; 182 (9) : 5836-45.
P.119 掲載の参考文献
2) Ishiuji Y. Addiction and the itch-scratch cycle : What do they have in common? Exp Dermatol 2019 ; 28 : 1448-54.
3) Fry L. Psoriasis. Br J Dermatol 1988 ; 119 : 445-61.
4) Elewski B, Alexis AF, Lebwohl M, et al. Itch : An under-recognized problem in psoriasis. J Eur Acad Dermatol Venereol 2019 ; 33 : 1465-76.
5) 山田秀和, 杉原和子, 柳下晃一. VASスケールにおける掻破とそう痒について-皮膚疾患による違いについて. 皮膚の科学 2002 ; 1 : 45-8.
6) Shahwan KT, Kimball AB. Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis : A meta-analysis. J Am Acad Dermatol 2017 ; 76 : 1198-200.
7) Kubanov AA, Bakulev AL, Fitileva TV, et al. Disease burden and treatment patterns of psoriasis in Russia : A real-world patient and dermatologist survey. Dermatol Ther (Heidelb) 2018 ; 8 : 581-92.
8) Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis : End of the drought? J Allergy Clin Immunol 2017 ; 140 : 633-43.
9) Wilson SR, The L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013 ; 155 : 285-95.
10) Volpe E, Pattarini L, Martinez-Cingolani C, et al. Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis. J Allergy Clin Immunol 2014 ; 134 : 373-81.
11) Narbutt J, Olejniczak I, Sobolewska-Sztychny D, et al. Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res 2013 ; 305 : 191-5.
12) Niyonsaba F, Ushio H, Hara M, et al. Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 2010 ; 184 : 3526-34.
13) Xiao X, Yeoh BS, Vijay-Kumar M. Lipocalin 2 : An emerging player in iron homeostasis and inflammation. Annu Rev Nutr 2017 ; 37 : 103-30.
14) Shiratori-Hayashi M, Koga K, Tozaki-Saitoh H, et al. STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch. Nat Med 2015 ; 21 : 927-31.
15) Aizawa N, Ishiuji Y, Tominaga M, et al. Relationship between the degrees of itch and serum lipocalin-2 levels in patients with psoriasis. J Immunol Res 2019 ; 2019 : 8171373.
16) Gupta S, Sen U. More than just an enzyme : Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling. Pharmacol Res 2019 ; 147 : 104391.
17) Komiya E, Hatano R, Otsuka H, et al. A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus. J Dermatol Sci 2017 ; 86 : 212-21.
18) Rukwied RR, Main M, Weinkauf B, et al. NGF sensitizes nociceptors for cowhage- but not histamine-induced itch in human skin. J Invest Dermatol 2013 ; 133 : 268-70.
19) Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis : Results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol 2015 ; 95 : 542-8.
20) Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch : Involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 2014 ; 133 : 448-60.
21) Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol 2011 ; 165 : 277-84.
22) Takahashi N, Tominaga M, Kosaka R, et al. Involvement of μ-opioid receptors and κ-opioid receptors in itch-related scratching behaviour of imiquimod-induced psoriasis-like dermatitis in mice. Acta Derm Venereol 2017 ; 97 : 928-33.
23) Shimauchi T, Hirakawa S, Suzuki T, et al. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol 2013 ; 40 : 805-12.
24) Wong LS, Otsuka A, Yamamoto Y, et al. Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice. J Dermatol Sci 2016 ; 83 : 148-51.
25) Therene C, Brenaut E, Barnetche T, et al. Efficacy of systemic treatments of psoriasis on pruritus : A systemic literature review and meta-analysis. J Invest Dermatol 2018 ; 138 : 38-45.
26) Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks : A phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015 ; 173 : 1387-99.
27) Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol 2016 ; 96 : 514-20.
28) Keating GM. Apremilast : A review in psoriasis and psoriatic arthritis. Drugs 2017 ; 77 : 459-72.
29) Hashimoto T, Sakai K, Sanders KM, et al. Antipruritic effects of janus kinase inhibitor tofacitinib in a mouse model of psoriasis. Acta Derm Venereol 2019 ; 99 : 298-303.
P.125 掲載の参考文献
1) Weiss G, Shemer A, Trau H. The Kobner phenomenon : Review of the literature. J Eur Acad Dermatol Venereol 2002 ; 16 (3) : 241-8.
2) Yamamoto T, Kurihara K, Tokura Y. Tissue resident memory T cells in lesional and non-lesional psoriatic skin on a scar. J Dermatol 2020 ; 47 (5) : e210-1.
3) Gallais Serezal I, Hoffer E, Ignatov B, et al. A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis. J Allergy Clin Immunol 2019 ; 143 : 1444-54.
4) 植木宏明. サルコイドーシスにおけるケブネル現象その意味. 西日本皮膚科 2004 ; 16 : 1-5.
5) 山本俊幸. サルコイドーシスのケブネル現象. 日サ会誌 2017 ; 37 : 31-4.
6) Mirmirani P. Two birds that exclude each other : The Renbok phenomenon. J Invest Dermatol 2015 ; 135 (4) : 1180.
P.126 掲載の参考文献
1) Happle R, van der Steen PHM, Perret CM. The Renbok phenomenon : An inverse Kobner reaction observed in alopecia areata. Eur J Dermatol 1991 ; 1 : 228-30.
2) Chen W. Alopecia areata universalis sparing nevus flammeus. Dermatology 2005 ; 210 : 227-8.
3) Yamamoto T, Okabe H, Hoshi M. Alopecia totalis sparing congenital melanocytic nevus : Renbok phenomenon. Dermatol Sinica 2019 ; 37 : 176-7.
P.127 掲載の参考文献
1) Yesudian PD, Chalmers RJ, Warren RB, et al. In search of oral psoriasis. Arch Dermatol Res 2012 ; 304 : 1-5.
2) Pietrzak D, Pietrzak A, Krasowska D, et al. Digestive system in psoriasis : An update. Arch Dermatol Res 2017 ; 309 : 679-93.
3) Gonzalez-Alvarez L, Garcia-Martin JM, Garcia-Pola MJ, et al. Association between geographic tongue and psoriasis : A systematic review and meta-analyses. J Oral Pathol Med 2019 ; 48 : 365-72.
4) Liang J, Huang P, Li H, et al. Mutations in IL36RN are associated with geographic tongue. Hum Genet 2017 ; 136 : 241-52.
5) Yamamoto T, Nishioka K. Successful treatment with topical tacrolimus for oral psoriasis. J Eur Acad Dermatol Venereol 2006 ; 20 : 1137-8.
6) Marti N, Pinazo I, Revert A, et al. Psoriasis of the lips. J Dermatol Case Rep 2009 ; 3 : 50-2.
7) Yao XJ, Zhang TD. Psoriasis localized to the glans penis in a 37-year-old man. CMAJ 2018 ; 190 : E747.
8) Albert S, Neill S, Derrick EK, et al. Psoriasis associated with vulval scarring. Clin Exp Dermatol 2004 ; 29 : 354-6.
P.134 掲載の参考文献
1) Naito R, Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan : A hospital-based case-control study. J Dermatol 2016 ; 43 : 1406-11.
2) Bayaraa B, Imafuku S. Relationship between environmental factors, age of onset and familial history in Japanese patients with psoriasis. J Dermatol 2018 ; 45 : 715-8.
3) Flugman SL, McClain SA, Clark RA. Transient eruptive seborrheic keratoses associated with erythrodermic psoriasis and erythrodermic drug eruption : Report of two cases. J Am Acad Dermatol 2001 ; 45 : S212-4.
4) Takahashi H, Tsuji H, Takahashi I, et al. Prevalence of obesity/adiposity in Japanese psoriasis patients : Adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009 ; 55 : 74-6.
5) Imafuku S, Nakayama J. Profile of patients with psoriasis associated with hepatitis C virus infection. J Dermatol 2013 ; 40 : 428-33.
6) Yamamoto T, Katayama I, Nishioka K. Psoriasis and hepatitis C virus. Acta Derm Venereol 1995 ; 75 : 482-3.
7) Chouela E, Abeldano A, Panetta J, et al. Hepatitis C virus antibody (anti-HCV) : Prevalence in psoriasis. Int J Dermatol 1996 ; 35 : 797-9.
8) Cohen AD, Weitzman D, Birkenfeld S, et al. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 2010 ; 220 : 218-22.
9) Imafuku S, Nakayama J. Questionnaire-based survey of the treatment of patients with psoriasis and hepatitis C in Japan. J Eur Acad Dermatol Venereol 2010 ; 24 : 1114-6.
10) Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C : A correlation with histological fibrosis and activity. J Hepatol 1999 ; 30 : 185-91.
11) Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection : A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005 ; 42 : 315-22.
12) Knobler H, Schattner A. TNF- {alpha}, chronic hepatitis C and diabetes : A novel triad. QJM 2005 ; 98 : 1-6.
13) Lebrun D, Hentzien M, Cuzin L, et al. Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort. AIDS 2017 ; 31 : 2159-66.
14) Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol 2018 ; 178 : 854-62.
15) Mallon E, Young D, Bunce M, et al. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 1998 ; 139 : 527-33.
16) Wacleche VS, Landay A, Routy JP, et al. The Th17 Lineage : From Barrier Surfaces Homeostasis to Autoimmunity, Cancer, and HIV-1 Pathogenesis. Viruses 2017 ; 9 : E303.
17) Ohtsuka M, Miura T, Mori T, et al. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol 2015 ; 151 : 797-9.
18) Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol 2017 ; 47 : 765-79.
P.137 掲載の参考文献
1) Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with metotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996 ; 14 : 1943-9.
2) Lee JW, Jung KJ, Kim TG et al. Risk of malignancy in patients with psoriasis : a 15-year nationwide population-based prospective cohort study in Korea. J Eur Acad Dermatol Venereol. 2019 ; 33 : 2296-304.
3) Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019 ; 80 (4) : 1073-113.
4) Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/dcpc/prevention/screening.htm
5) 日本リウマチ学会ガイドライン委員会・RA治療薬ガイドライン小委員会. 関節リウマチ (RA) に対するTNF阻害薬使用の手引き (2020年2月1日改訂版). https://www.ryumachi-jp.com/publish/guide/guideline_tnf/
6) 大槻マミ太郎, 佐伯秀久, 照井正ほか. 乾癬における生物学的製剤の使用ガイダンス (2019年版). 日皮会誌 2019 ; 129 : 1845-64.
P.144 掲載の参考文献
1) Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med 2015 ; 21 (7) : 688-97.
2) Watanabe R. Protective and pathogenic roles of resident memory T cells in human skin disorders. J Dermatol Sci 2019 ; 95 (1) : 2-7.
3) Vo S, Watanabe R, Koguchi-Yoshioka H, et al. CD8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-naive nonlesional sites of psoriasis possibly in correlation with disease duration. Br J Dermatol 2019 ; 181 (2) : 410-2.
4) Serezal IG, Hoffer E, Ignatovet B, et al. A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis. J Allergy Clin Immunol 2019 ; 143 : 1444-54.
5) Fyhrquist N, Muirhead G, Prast-Nielsen S, et al. Microbe-host interplay in atopic dermatitis and psoriasis. Nat Commun 2019 ; 10 : 4703.
6) Chang HW, Yan D, Singh R, et al. Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome 2018 ; 6 : 154.
7) Kurihara K, Fujiyama T, Phadungsaksawasdi P, et al. Significance of IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course. J Dermatol Sci 2019 ; 95 : 21-7.
P.151 掲載の参考文献
Atas H, Gonul M. Insulin resistance, diabetes mellitus and thyroid dysfunction in patients with palmoplantar pustulosis : A case-controlled study. Postepy Dermatol Alergol 2017 ; 34 (3) : 268-72.
Bayaraa B, Imafuku S. Relationship between environmental factors, age of onset and familial history in Japanese patients with psoriasis. J Dermatol 2018 ; 45 (6) : 715-8.
Brunasso AM, Puntoni M, Aberer W, et al. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis : A case series study. Br J Dermatol 2013 ; 168 (6) : 1243-51.
Garshick MK, Kimball AB. Psoriasis and the life cycle of persistent life effects. Dermatol Clin 2015 ; 33 (1) : 25-39.
Iskandar IYK, Ashcroft DM, Warren RB, et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol 2017 ; 177 (5) : 1410-21.
La Vecchia C, Gallus S, Naldi L. Tobacco and skin disease. Dermatology 2005 ; 211 (2) : 81-3.
Lee EJ, Han KD, Han JH, et al. Smoking and risk of psoriasis : A nationwide cohort study. J Am Acad Dermatol 2017 ; 77 (3) : 573-5.
Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis : Do we need to change? Br J Dermatol 2011 ; 164 (5) : 942-6.
Naldi L, Mercuri SR. Smoking and psoriasis : From epidemiology to pathomechanisms. J Invest Dermatol 2009 ; 129 (12) : 2741-3.
Olazagasti JM, Ma JE, Wetter DA. Clinical Features, Etiologic Factors, Associated Disorders, and Treatment of Palmoplantar Pustulosis : The Mayo Clinic Experience, 1996-2013. Mayo Clin Proc 2017 ; 92 (9) : 1351-8.
Patil S, Apurwa A, Nadkarni N, et al. Hidradenitis Suppurativa : Inside and Out. Indian J Dermatol 2018 ; 63 (2) : 91-8.
P.158 掲載の参考文献
1) Yamamoto T, Ohtsuki M, Sano S, el al. Prevalence and current therapies of psoriatic arthritis in Japan : A survey by the Japanese Society of Psoriasis Research in 2016. J Dermatol 2017 ; 44 : e121.
2) Takahashi H, Honma M, Ishida-Yamamoto A, et al. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci 2010 ; 59 : 143-5.
3) 下村伊一郎, 船橋徹, 松澤佑次. 肥満の役割-アディポサイトカインの産生異常. 日内会誌 2004 ; 93 (4) : 655-61.
4) Ogawa K, Stuart PE, Tsoi LC, et al. A transethnic Mendelian randomization study identities causality on risk of psoriasis. J Invest Dermatol 2019 ; 139 : 1397-400.
5) Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome : A systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013 ; 68 : 654-62.
6) Richard MA, Paul C. Cardiovascular morbidity, risk of cancer and alcohol abuse in psoriasis : Systematic literature reviews and expert opinion. J Euro Acad Dermatol Venereol Suppl 3 2013 : 30-5.
7) Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march' : A concept of how severe psoriasis may drive cardiovascular comorbidity, Exp Dermatol 2011 ; 20 : 303-7.
8) Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis : Results from a prospective observational study. Cardiovasc Res 2019 ; 115 : 721-8.
9) Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012 ; 148 : 1244-50.
10) Jokai H, Szakonyi J, Kontar O, et al. Impact of effective tumor necrosis factor-α inhibitor treatment on arterial intima-media thickness in psoriasis : Results of a pilot study. J Am Acad Dermatol 2013 ; 69 : 523-9
P.159 掲載の参考文献
1) Jacobsen T, Lie BA, Lysvand H, et al. Detection of psoriasis-associated antigen pso p27 in sarcoidosis bronchoalveolar lavage fluid using monoclonal antibodies. Clin Immunol Immunopathol 1996 ; 81 ; 82-7.
2) Iversen OJ, Lysvand H, Slupphaug G. Pso p27, a SERPINB3/B4-derived protein, is most likely a common autoantigen in chronic inflammatory diseases. Clin Immunol 2017 ; 174 ; 10-7.
3) Ishikawa M, Yamamoto T. Plaque-type psoriasis in a patient with sarcoidosis. Actas Dermosifiliogr (in press). 4) Yamamoto T, Nishibu A, Eishi Y. Transepidermal elimination of sarcoid granuloma in the lesional skin of psoriasiform sarcoidosis. J Dermatol 2017 ; 44 ; 100-1.
5) Ishikawa M, Ohashi T, Eishi Y, et al. Palmoplantar pustulosis in a patient with sarcoidosis. Eur J Dermatol 2020 ; 30 : 325-6.
6) Lin SH, Chuang HY, Ho JC, et al. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation. J Dermatol Sci 2018 ; 91 ; 276-84.
7) Nakamura-Wakatsuki T, Yamamoto T. Palmoplantar pustulosis associated with necrobiosis lipoidica ; A possible role of TNF-α and IL-17. J Dermatol 2014 ; 41 ; 461-2.
P.161 掲載の参考文献
1) Tselios K, Yap KS, Pakchotanon R, et al. Psoriasis in systemic lupus erythematosus : A single-center experience. Clin Rheumatol 2017 ; 36 : 879-84.
2) Yokogawa M, Takaishi M, Nakajima K, et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice : A new model of systemic lupus erythematosus. Arthritis Rheumatol 2014 ; 66 : 694-706.
3) Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus : Implications for Th17-mediated inflammation and autoimmunity. Clin Immunol 2008 ; 127 : 385-93.
4) Hoffmann JHO, Enk AH. Neutrophil extracellular traps in dermatology : Caught in the NET. J Dermatol Sci 2016 ; 84 : 3-10.
5) Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011 ; 187 : 538-52.
6) Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010 ; 107 : 9813-8.
7) Leffler J, Gullstrand B, Jonsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus, Arthritis Res Ther 2013 ; 15 : R84.
8) Hu SC, Yu HS, Yen FL, et al. Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes. Sci Rep 2016 ; 6 : 31119.
9) Lambert S, Hambro CA, Johnston A, et al. Neutrophil extracellular traps induce human Th17 cells : Effect of psoriasis-associated TRAF3IP2 genotype. J Invest Dermatol 2019 ; 139 : 1245-53.
P.162 掲載の参考文献
1) Yamamoto T, Katayama I, Nishioka K. A rare association of systemic sclerosis with psoriasis vulgaris. J Dermatol 2000 ; 27 : 346-9.
2) Chizzolini C, Dufour AM, Brembilla NC. Is there a role for IL-17 in the pathogenesis of systemic sclerosis? Immunol Lett 2018 ; 195 : 61-7.
3) Dufour AM, Borowczyk-Michalowska J, Alvarez M, et al. IL-17A dissociates inflammation from fibrogenesis in systemic sclerosis. J Invest Dermatol 2020 ; 140 : 103-12.
4) Zolkiewicz J, Stochmal A, Rudnicka L. The role of adipokines in systemic sclerosis : A missing link? Arch Dermatol Res 2019 ; 311 : 251-63.
P.164 掲載の参考文献
1) McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol 2008 ; 35 : 452-6.
2) Shrestha S, Wershil B, Sarwark JF, et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 2010 ; 62 : 2813-22.
3) Kato Y, Yamamoto T. Development of psoriasis with relapse of dermatomyositis-associated interstitial lung disease. Int J Rheum 2017 ; 20 : 660-1.
4) Silva MG, Oba-Shinjo SM, Marie SKN, et al. Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 2019 ; 37 : 656-62.
P.167 掲載の参考文献
1) Scarpa R, Ayala F, Caporaso N, et al. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006 ; 33 : 210-2.
2) Scarpa R, Caso F, Costa L, et al. Psoriatic Disease 10 Years Later. J Rheumatol 2017 ; 44 : 1298-301.
3) Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march' : A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011 ; 20 : 303-7.
4) Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis : A population-based cohort study in the United Kingdom. Br J Dermatol 2010 ; 163 : 586-92.
5) Mitsuyama S, Abe F, Kimura M, et al. Association between leptin gene expression in subcutaneous adipose tissue and circulating leptin levels in obese patients with psoriasis. Arch Dermatol Res 2015 ; 307 : 539-44.
P.172 掲載の参考文献
五十嵐敦之. 尋常性乾癬とその鑑別疾患. 大槻マミ太郎 (編). 皮膚科臨床アセット 10. ここまでわかった乾癬の病態と治療. 中山書店 ; 2012. pp.87-93.
Lever WF, Schaumburg-Lever G. Histopathology of the Skin, 7th edition. JB Lippincott ; 1990.
Patterson JW. Weedon's Skin Pathology, 4th edition. Churchil Livingstone ; 2016.
山元修. 乾癬の病理組織像. 大槻マミ太郎 (編). 皮膚科臨床アセット 10. ここまでわかった乾癬の病態と治療. 中山書店 ; 2012. pp.53-7.
山元修. 乾癬の病理組織. 日本臨牀 2018 ; 76 : 28-33.
P.174 掲載の参考文献
1) Usatine RP, Tinitigan M. Diagnosis and treatment of lichen planus. Am Fam Physician 2011 ; 84 : 53-60.
2) Lallas A, Kyrgidis A, Tzellos TG, et al. Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea. Br J Dermatol 2012 ; 166 : 1198-205.
3) Tziotzios C, Brier T, Lee JYW, et al. Lichen planus and lichenoid dermatoses : Conventional and emerging therapeutic strategies. J Am Acad Dermatol 2018 ; 79 : 807-18.
4) Tziotzios C, Lee JYW, Brier T, et al. Lichen planus and lichenoid dermatoses : Clinical overview and molecular basis. J Am Acad Dermatol 2018 ; 79 : 789-804.
5) Yamamoto T, Katayama I, Nishioka K. Absence of restricted T cell receptor V beta repertoire in skin lesions of a patient with both psoriasis vulgaris and lichen planus. Dermatology 1996 ; 192 : 67-9.
6) Solimani F, Pollmann R, Schmidt T, et al. Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus. Front Immunol 2019 ; 10 : 1808.
P.181 掲載の参考文献
1) 中川秀己, 五十嵐敦之, 江藤隆史ほか. 乾癬における患者満足度調査 (第二報) -患者満足度に影響を及ぼす因子の検討. 日皮会誌 2005 ; 115 : 1449-59.
2) Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris : A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002 ; 147 : 316-23.
4) 中川秀己, 河井雅彦, 伊藤嘉奈子. 尋常性乾癬患者を対象としたマキサカルシトールおよびベタメタゾン酪酸エステルプロピオン酸-エステル外用配合薬の第III相臨床試験. 西日皮膚 2015 ; 77 : 390-8.
5) 五十嵐敦之. 乾癬治療におけるカルシポトリオール水和物+ベタメタゾンジプロピオン酸エステル配合外用薬の効果の検討. 日臨皮医誌 2017 ; 34 : 462-7.
P.183 掲載の参考文献
1) Ortonne J, Chimenti S, Luger T, et al. Scalp psoriasis : European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol 2009 ; 23 : 1435-44.
2) van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998 ; 197 : 326-34.
3) Shiiya C, Nomura Y, Fujita Y, et al. Psoriasis vulgaris with fibrokeratoma from pityriasis amiantacea. JAAD Case Rep 2017 ; 3 : 243-5.
4) Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis : A population-based study. Arthritis Rheum 2009 ; 61 : 233-9.
5) Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol 2014 ; 171 : 1123-8.
P.189 掲載の参考文献
1) 森田明理. 乾癬治療を整理しよう-光線療法. 皮膚臨床 2018 ; 60 ; 1501-5.
2) 森田明理, 江藤隆史, 鳥居秀嗣ほか. 乾癬の光線療法ガイドライン. 日皮会誌 2016 ; 126 : 1239-62.
3) Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol 2019 ; 81 : 775-804.
4) Raone B, Patrizi A, Gurioli C, et al. Cutaneous carcinogenic risk evaluation in 375 patients treated with narrowband-UVB phototherapy : A 15-year experience from our Institute. Photodermatol Photoimmunol Photomed 2018 ; 34 : 302-6.
5) Bagel J, Nelson E, Keegan BR. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis. J Drugs Dermatol 2017 ; 16 : 957-62.
P.196 掲載の参考文献
2) Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004 ; 140 : 408-14.
3) Liu J, Chen M, Wang X. Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 2000 ; 101 : 61-7.
4) Jimenez JL, Punzon C, Navarro J, et al. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001 ; 299 : 753-9.
5) Sheibanie AF, Tadmori I, Jing H, et al. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J 2004 ; 18 : 1318-20.
6) Ohtsuki M, Okubo Y, Komine M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis : Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol 2017 ; 44 : 873-84.
7) Cutolo M, Myerson GE, Fleischmann RM, et al. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis : Results of the PALACE 2 Trial. J Rheumatol 2016 ; 43 : 1724-34.
8) 岸本恵美, 神谷浩二, 菅井順一ほか. 乾癬におけるアプレミラスト使用時のコツと注意点. Visual Dermatology 2019 ; 18 : 992-7.
9) 安部正敏. どうつかう? アプレミラスト. Visual Dermatology 2019 ; 18 : 978-83.
10) 清島真理子, 北島康雄. レチノイド内服・外用薬. Derma 1999 ; 26 : 17-25.
11) 多田弥生. エトレチナートの薬理作用. Visual Dermatology 2017 ; 16 : 889.
12) Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin 2004 ; 22 : 467-76, x.
13) 梅澤慶紀, 朝比奈昭彦, 中川秀己. シクロスポリンとエトレチナート. Derma 2016 : 43-9.
14) 大槻マミ太郎. 皮膚科のMTXバイブル-旧薬誓書から新薬成書へ. Visual Dermatology 2019 ; 18 : 14-24.
15) Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016 ; 68 : 1060-71.
P.203 掲載の参考文献
1) 日本皮膚科学会乾癬生物学的製剤検討委員会. 乾癬における生物学的製剤の使用ガイダンス (2019年版). 日皮会誌 2019 ; 129 : 1845-64.
2) O'Meara S, Nanda S, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease : A systematic review and meta-analysis. Inflamm Bowel Dis 2014 ; 20 : 1-6.
3) 日本呼吸器学会生物学的製剤と呼吸器疾患・診療の手引き作成委員会. 生物学的製剤と呼吸器疾患診療の手引き. 日本呼吸器学会ホームページ ; 2017. https://www.jrs.or.jp/modules/guidelines/index.php?content_id=69
4) 日本肝臓学会肝炎診療ガイドライン作成委員会. B型肝炎治療ガイドライン (第3.1版). 日本肝臓学会ホームページ ; 2019. https://www.jsh.or.jp/medical/guidelines/
5) 日本リウマチ学会ガイドライン委員会RA治療薬ガイドライン小委員会. 関節リウマチ (RA) に対する TNF阻害薬使用ガイドライン (2019年6月29日改訂版). 日本リウマチ学会ホームページ ; 2019. https://www.ryumachi-jp.com/publish/guide/guideline_tnf/
P.208 掲載の参考文献
1) 菅井順一, 中川秀己. アンケート結果にみる乾癬患者の薬剤使用の実態. Mebio 2002 ; 19 : 8-11.
2) 菅井順一, 平嶋海帆, 大槻マミ太郎ほか. 軽症から中等症の乾癬患者における低用量ネオーラル内服療法の有用性とQOL改善の検討. 日臨皮医誌 2007 ; 24 : 62-6.
3) 森田明理, 江藤隆史, 鳥居秀嗣ほか. 乾癬の光線療法ガイドライン. 日皮会誌 2016 ; 126 : 1239-62.

3章 乾癬の特殊型

P.216 掲載の参考文献
2) Ito T, Takahashi H, Kawada A, et al ; Japanese Society For Psoriasis Research. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol 2018 ; 45 : 293-301.
3) Mehlis S. Guttate psoriasis. Ofori AO (ed), UpToDate(R). Waltham. https://www.uptodate.com (accessed on November 13, 2019)
4) Ruiz-Romeu E, Ferran M, Sagrista M, et al. Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis. J Allergy Clin Immunol 2016 ; 138 : 491-9.
5) Dupire G, Droitcourt C, Hughes C, et al. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev 2019 ; 3 : CD011571.
P.220 掲載の参考文献
1) Boyd AS, Menter A, Erythrodermic psoriasis : Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989 ; 21 (5 Pt 1) : 985-91.
2) Xing X, Liang Y, Sarkar MK, et al. IL-17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic plaque psoriasis. J Invest Dermatol 2016 ; 136 (12) : 2498-501.
3) Yamasaki K, Nakagawa H, Kubo Y, et al ; Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma : Results from a 52-week, open-label study. Br J Dermatol 2017 ; 176 (3) : 741-51.
4) Zhang P, Chen HX, Duan YQ, et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Technolog Med Sci 2014 ; 34 (4) : 596-601.
5) Li LF, Sujan SA, Yang H, et al. Serum immunoglobulins in psoriatic erythroderma. Clin Exp Dermatol 2005 ; 30 (2) : 125-7.
6) Moy AP, Murali M, Kroshinsky D, et al. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis. JAMA Dermatol 2015 ; 151 (7) : 753-60.
7) Deeva I, Mariani S, De Luca C, et al. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine 2010 ; 49 (2) : 163-70.
8) Signa S, Campione E, Rusmini M, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. Pediatr Rheumatol Online J 2019 ; 17 (1) : 38.
9) Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption : A spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol 2018 ; 79 (3) : 487-94.
P.224 掲載の参考文献
1) 今福信一, 中山樹一郎. 乾癬と脂漏性皮膚炎. MB Derma 2012 ; 195 : 49-53.
1) 今福信一, 中山樹一郎. 脂漏性乾癬. 大槻マミ太郎 (編). 皮膚科臨床アセット 10. ここまでわかった乾癬の病態と治療. 中山書店 ; 2012. pp.117-9.
2) Merola JF, Li T, Li WQ, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016 ; 41 : 486-9.
3) Weedon D. Psoriasis. In : Weedon D (ed). Skin Pathology, 2nd edition. Elsevier ; 2002. pp.80-1.
4) 斉藤隆三, 伊藤直子, 伊勢信子. 小児の乾癬ならびにNapkin Psoriasisについて. 皮膚科の臨床 1973 ; 15 : 676-81.
5) Iinuma S, Matsuo R, Fujii M, et al. Psoriasis verrucosa complicated by generalized pustular psoriasis. J Dermatol 2018 ; 45 : e57-8.
6) Khalil FK, Keehn CA, Saeed S, et al. Verrucous psoriasis : A distinctive clinicopathologic variant of psoriasis. Am J Dermatopathol 2005 ; 27 : 204-7.
P.229 掲載の参考文献
1) Balak DM, Hajdarbegovic E. Drug-induced psoriasis : Clinical perspectives. Psoriasis (Auckl) 2017 ; 7 : 87-94.
2) Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008 ; 30 (4) : 352-69.
3) 内田敬久, 佐野沙織, 渡邊友也ほか. 薬剤性乾癬34例の検討. 日皮会誌 2016 : 126 : 295-302.
4) Wu S, Han J, Li WQ, et al. Hypertension, antihypertensive medication use, and risk of psoriasis.JAMA Dermatol 2014 ; 150 : 957-63.
5) Brauchli YB, Jick SS, Curtin F, et al. Lithium, antipsychotics, and risk of psoriasis. J Clin Psychopharmacol 2009 ; 29 : 134-40.
6) Armstrong AW. Psoriasis provoked or exacerbated by medications : Identifying culprit drugs. JAMA Dermatol 2014 ; 150 : 963.
7) Guerra I, Perez-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease : A nationwide cohort study. Inflamm Bowel Dis 2016 ; 22 : 894-901.
8) Imai Y, Ayithan N, Wu X, et al. Cutting edge : PD-1 regulates imiquimod-induced psoriasiform dermatitis through inhibition of IL-17A expression by innate γδ-low T cells. J Immunol 2015 ; 195 : 421-5.
9) Tsutsumi R, Yoshida Y, Yamamoto O. Imiquimod-induced psoriatic erythroderma treated with infliximab. Acta Derm Venereol 2017 ; 97 : 279-80.
P.231 掲載の参考文献
1) Puig L. Paradoxical Reactions : Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. Curr Probl Dermatol 2018 ; 53 : 49-63.
2) Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy : Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2009 ; 40 : 233-40.
3) Conrad C, Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018 ; 9 : 25-36.
4) Takahashi H, Sato K, Takagi A, et al. Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis. J Dermatol 2018 ; 45 : e325-6.

4章 乾癬性関節炎

P.240 掲載の参考文献
1) Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis : A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019 ; 80 : 251-65, e19.
2) Ohara Y, Kishimoto M, Takizawa N, et al. Prevalence and clinical characteristics of psoriatic arthritis in Japan. J Rheumatol 2015 ; 42 : 1439-42.
3) Yamamoto T, Ohtsuki M, Sano S, et al. Prevalence and Current Therapies of Psoriatic Arthritis in Japan : A Survey by the Japanese Society of Psoriasis Research in 2016. J Dermatol 2017 ; 44 : e121.
4) Yamamoto T, Ohtsuki M, Sano S, et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol 2016 ; 43 : 1193-6.
5) Solmaz D, Eder L, Aydin SZ. Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis. Best Pract Res Clin Rheumatol 2018 ; 32 : 295-311.
6) Solmaz D, Bakirci S, Kimyon G, et al. Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res (Hoboken) 2020 ; 72 : 63-8.
P.244 掲載の参考文献
1) Zenke Y, Ohara Y, Kobayashi D, et al. Nail findings in patients with psoriatic arthritis : A cross-sectional study with special reference to transverse grooves. J Am Acad Dermatol 2017 ; 77 : 863-7.
2) Ikumi K, Kobayashi S, Tamura N, et al. HLA-B46 is associated with severe sacroiliitis in Japanese patients with psoriatic arthritis. Mod Rheumatol 2019 ; 29 : 1017-22.
3) Gracey E, Burssens A, Cambre I, et al. Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. Nat Rev Rheumatol 2020 ; 16 : 193-207.
P.251 掲載の参考文献
1) Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012 ; 64 : 99-109.
2) Yamamoto T, Yokozeki H, Nishioka K. Clinical analysis of 21 patients with psoriasis arthropathy. J Dermatol 2005 ; 32 : 84-90.
3) Yamamoto T. Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol 2013 ; 2013 : 630620.
4) Belasco J, Louie JS, Gulati N, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol 2015 ; 67 : 934-44.
5) Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Moll Cell Biochem 2012 ; 359 : 419-29.
P.252 掲載の参考文献
1) Steel KJ, Srenathan U, Ridley M, et al. Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+ CD8+ T cells in psoriatic arthritis. Arthritis Rheumatol 2020 ; 72 : 435-47.
2) Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+ CD4- CD8- entheseal resident T cells. Nat Med 2012 ; 18 : 1069-76.
3) Ono T, Okamoto K, Nakashima T, et al. IL-17-producing γδ T cells enhance bone regeneration. Nat Commun 2016 ; 7 : 10928.
4) Ikebuchi Y, Aoki S, Honma M, et al. Coupling of bone resorption and formation by RANKL reverse signaling. Nature 2018 ; 561 : 195-200.
5) Zaidi M, Cardozo CP. Receptor becomes a ligand. Nature 2018 ; 561 : 180-1.
6) Cuthbert RJ, Watad A, Fragkakis EM, et al. Evidence that tissue resident human enthesis γδ T-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis 2019 ; 78 : 1559-65.
7) McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis : Recent advances and controversies. Ann Rheum Dis 2019 ; 78 : 1167-78.
P.256 掲載の参考文献
1) Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis : Development of new criteria from a large international study. Arthritis Rheum 2006 ; 54 (8) : 2665-73.
2) McGonagle D, Tan AL, Watad A, et al. Pathophysiology, assessment and treatment of psoriatic dactylitis. Nat Rev Rheumatol 2019 ; 15 (2) : 113-22.
3) Bakewell CJ, Olivieri I, Aydin SZ, et al. Ultrasound and magnetic resonance imaging in the evaluation of psoriatic dactylitis : Status and perspectives. J Rheumatol 2013 ; 40 (12) : 1951-7.
4) Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials : Which is the best instrument to use? J Rheumatol 2007 ; 34 (6) : 1302-6.
P.264 掲載の参考文献
1) 佐野栄紀. 関節症乾癬とその成因. 皮膚病診療 2010 ; 32 : 1160-5.
4) Walter A, Schafer M, Cecconi V, et al. Aldara activates TLR7-independent immune defence. Nat Commun 2013 ; 4 : 1560-72.
5) Ohtani T, Ishihara K, Atsumi T, et al. Dissection of signaling cascades through gp130 in vivo : Reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 2000 ; 12 : 95-105.
6) Yamamoto M, Nakajima K, Takaishi M, et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol 2015 ; 135 : 445-53.
7) Takata T, Taniguchi Y, Ohnishi T, et al. (18) FDG PET/CT is a powerful tool for detecting subclinical arthritis in patients with psoriatic arthritis and/or psoriasis vulgaris. J Dermatol Sci 2011 ; 64 (2) : 144-7.
8) Takata T, Takahashi A, Taniguchi Y, et al. Detection of asymptomatic enthesitis in psoriasis patients : An onset of psoriatic arthritis? J Dermatol 2016 ; 43 : 650-4.
P.265 掲載の参考文献
1) Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis : Development of new criteria from a large international study. Arthritis Rheum 2006 ; 54 : 2665-73.
2) Errichetti E, Zabotti A, Stinco G, et al. Dermoscopy of nail fold and elbow in the differential diagnosis of early psoriatic arthritis sine psoriasis and early rheumatoid arthritis. J Dermatol 2016 ; 43 : 1217-20.
3) Scarpa R, Cosentini E, Manguso F, et al. Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". J Rheumatol 2003 ; 30 : 2638-40.
4) Caso F, Postiglione L, Covelli B, et al. Pro-inflammatory adipokine profile in psoriatic arthritis : Results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis". Clin Rheumatol 2019 ; 38 : 2547-52.
P.271 掲載の参考文献
1) Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force. Ann Rheum Dis 2018 ; 77 : 3-17.
2) Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis : A proposed objective target for treatment. Ann Rheum Dis 2010 ; 69 : 48-53.
3) Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016 ; 68 : 1060-71.
4) Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis : A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004 ; 50 : 1939-50.
5) Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012 ; 51 : 1368-77.
6) Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014 ; 73 : 1020-6.
7) Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis : A phase IIIB, randomized controlled trial (ACTIVE). Ann Rheum Dis 2018 ; 77 : 690-8.
8) Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis : Results of the IMPACT 2 trial. Ann Rheum Dis 2005 ; 64 : 1150-7.
9) Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) : Results of radiographic analyses after 1 year. Ann Rheum Dis 2006 ; 65 : 1038-43.
10) Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis : Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 ; 52 : 3279-89.
11) Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis : 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014 ; 73 : 48-55.
12) Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy : Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018 ; 77 : 228-33.
13) McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2) : A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015 ; 386 : 1137-46.
14) Mease P, van der Heijde D, Landewe R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression : Primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018 ; 77 : 890-7.
15) Mease PJ, van der Heijde D, Ritchlin CT, et al ; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis : Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab) -controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 2017 ; 76 : 79-87.
16) Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014 ; 370 : 2295-306.
17) McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis : 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled PSUMMIT 1 trial. Lancet 2013 ; 382 : 780-9.
18) Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis : Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014 ; 73 : 1000-6.
19) Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis : A randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2018 ; 391 : 2213-24.
20) Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate moderate-to-severe plaque psoriasis (UltlMMa-1 and UltlMMa-2) : Results from two double-blind, randomized, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018 ; 392 : 650-61.
21) Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-tosevere plaque psoriasis (IMMvent) : A randomized, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019 ; 394 : 576-86.
22) Gossec L, Smolen J, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update. Ann Rheum Dis 2016 ; 75 : 499-510.
P.276 掲載の参考文献
1) Ohara Y, Kishimoto M, Takizawa N, et al. Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. J Rheumatol 2015 ; 42 : 1439-42.
2) 山本俊幸, 大槻マミ太郎, 佐野栄紀ほか. 本邦乾癬性関節炎患者の疫学調査-日本乾癬学会による3年間の集計結果. 日皮会誌 2018 ; 128 : 2835-41.
3) Tsuruta N, Imafuku S, Narisawa Y, et al. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol 2017 ; 44 : 1349-52.
4) 多田弥生. 乾癬と尿酸代謝. 大槻マミ太郎 (編). 皮膚科臨床アセット 10, ここまでわかった乾癬の病態と治療. 中山書店 ; 2012. pp.177-9.
5) 杉原毅彦. 特集リウマチ性疾患と動脈硬化, 血清反応陰性脊椎関節症 (乾癬性関節炎). 炎症と免疫 2017 ; 25 : 216-8.
P.279 掲載の参考文献
P.281 掲載の参考文献
1) Taccari E, Spadaro A, Riccieri V, et al. Sternoclavicular joint disease in psoriatic arthritis. Ann Rheum Dis 1992 ; 51 : 372-4.
2) Mejjad O, Daragon A, Louvel JP, et al. Osteoarticular manifestations of pustulosis palmaris et plantaris and of psoriasis : Two distinct entities. Ann Rheum Dis 1996 ; 55 : 177-80.
3) Brzezinska-Wcislo L, Bergler-Czop B, Lis-Swiety A. Sonozaki syndrome : Case report and review of literature. Rheumatol Int 2012 ; 32 : 473-7.
4) Fragoulis GE, Evangelatos G, Konsta M, et al. Anterior chest wall involvement in psoriatic arthritis : A forgotten entity? Rheumatology (Oxford) 2020 ; keaa145.
5) Depasquale R, Kumar N, Lalam RK, et al. SAPHO : What radiologists should know. Clin Radiol 2012 ; 67 : 195-206.

5章 膿疱性乾癬

P.289 掲載の参考文献
1) 照井正, 秋山真志, 池田志斈ほか. 膿疱性乾癬 (汎発型) 診療ガイドライン 2014年度版. 日皮会誌 2015 ; 125 (12) : 2211-57.
2) von Zumbusch LR. Psoriasis und Pustulosis Exantem. Arch Dermatol Syph 1910 ; 99 : 335-46.
3) 山本俊幸. SAPHO症候群およびその類縁疾患. 臨床皮膚科 2017 ; 71 (5) : 25-9.
P.292 掲載の参考文献
1) Akiyama M, Takeichi T, McGrath JA, et al. Autoinflammatory keratinization diseases. J Allergy Clin Immunol 2017 ; 140 : 1545-7.
2) 照井正, 秋山真志, 池田志斈ほか. 膿疱性乾癬 (汎発型) 診療ガイドライン 2014年度版. 日皮会誌 2015 ; 125 : 2211-57.
3) 厚生労働省. 重篤副作用疾患別対応マニュアル 急性汎発性発疹性膿疱症. 2009. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1a13.pdf
5) Keller M, Spanou Z, Shaerli P, et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol 2005 ; 175 : 7678-86.
6) 池澤善郎. 急性汎発性発疹性膿疱症. ドクターサロン 2013 ; 57 : 193-8.
7) 杉浦一充. 汎発性膿疱性乾癬のバイオマーカー. 日薬理誌 2015 ; 146 : 252-5.
8) Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 2013 ; 133 : 1904-7.
9) 渡辺愛子, 米田真理, 庄田裕紀子. 急性汎発性発疹性膿疱症 (AGEP) 発症後, 汎発性膿疱性乾癬 (GPP) へ移行した一卵性双生児の兄弟例. 皮膚の科学 2012 ; 11 : 209-14.
10) Song HS, Kim SJ, Park TI, et al. Immunohistochemical comparison of IL-36 and the IL-23/Th17 axis of generalized pustular psoriasis and acute generalize exanthematous pustulosis. Ann Dermatol 2016 ; 28 : 451-6.
11) Vyas NS, Charifa A, Desman GT, et al. Distinguishing pustular psoriasis and acute generalized exanthematous pustulosis on the basis of plasmacytoid dendritic cells and MxA protein. J Cutan Pathol 2019 ; 46 : 317-26.
P.298 掲載の参考文献
1) 照井 正, 秋山真志, 池田志斈ほか. 膿疱性乾癬 (汎発型) 診療ガイドライン 2014年度版. 日皮会誌 2015 ; 125 : 2211-57.
2) 照井正, 中川秀己, 江藤隆史ほか. 健康保険組合レセプト情報を利用した乾癬の実態調査. 臨床医薬 2014 ; 30 : 279-85.
3) 安田秀美, 小林仁, 大河原章ほか. 本邦における膿疱性乾癬の疫学. 日皮会誌 1992 ; 102 : 971-6.
4) 安田秀美, 小林仁, 大河原章ほか. 本邦における小児汎発性膿疱性乾癬の疫学. 日皮会誌 1994 ; 104 : 759-66.
5) Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis : Analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2014 ; 53 : 676-84.
6) 岩月啓氏, 松浦浩徳, 大藤玲子ほか. 小児膿疱性乾癬の本邦における実態と臨床特徴. 日小皮会誌 2004 ; 23 : 126-31.
7) 厚生労働省. 平成29年度厚生労働科学研究費補助金 (難治性疾患政策研究事業) 分担研究報告書稀少難治性皮膚疾患に関する調査研究. 厚生労働科学研究成果データベース ; 2018. https://mhlw-grants.niph.go.jp/niph/search/NIDD02.do?resrchNum=201711080A
P.299 掲載の参考文献
1) Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march' : A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011 ; 20 (4) : 303-7.
2) Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases : Implications for management. J Am Acad Dermatol 2017 ; 76 (3) : 393-403.
3) Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis : Analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2014 ; 53 (6) : 676-84.
4) Ito T, Takahashi H, Kawada A, et al. Japanese Society For Psoriasis Research. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol 2018 ; 45 (3) : 293-301.
5) Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 2013 ; 133 (11) : 2514-21.
6) Sugiura K, Muto M, Akiyama M. CARD14 c.526G > C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol 2014 ; 134 (6) : 1755-7.
P.301 掲載の参考文献
1) Hussain S, Berki DM, Choon SE, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol 2015 ; 135 : 1067-70.e9.
P.304 掲載の参考文献
1) Akiyama M, Takeichi T, McGrath JA, et al. Autoinflammatory keratinization diseases. J Allergy Clin Immunol 2017 ; 140 : 1545-7.
2) Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011 ; 365 : 620-8.
3) Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 2013 ; 133 : 2514-21.
4) Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol 2017 ; 140 : 109-20.
5) Mellett M, Meier B, Mohanan D, et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo. J Invest Dermatol 2018 ; 138 : 2010-23.
P.305 掲載の参考文献
1) Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol 2019 ; 5 : 141-50.
2) Lin X, Huang T. Impact of pregnancy and oestrogen on psoriasis and potential therapeutic use of selective oestrogen receptor modulators for psoriasis. J Eur Acad Dermatol Venereol 2016 ; 30 : 1085-91.
3) Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005 ; 141 : 601-6.
4) Berman M, Zisman D, Wollman J, et al. The effect of pregnancy on disease activity in patients with psoriatic arthritis. J Rheumatol 2018 ; 45 : 1651-5.
5) Woidacki K, Zenclussen AC, Siebenhaar F. Mast cell-mediated and associated disorders in pregnancy : A risky game with an uncertain outcome? Front Immunol 2014 ; 5 : 231.
6) Vena GA, Cassano N, Bellia G, et al. Psoriasis in pregnancy : Challenges and solutions. Psoriasis (Auckl) 2015 ; 5 : 83-95.
7) 西岡清. 疱疹状膿痂疹. 西岡清 (監), 片山一朗ほか (監訳). 原著に学ぶ英米皮膚科学の古典. 大阪大学皮膚科学教室 ; 2018. pp.187-9.
P.311 掲載の参考文献
1) 日本皮膚科学会膿疱性乾癬 (汎発型) 診療ガイドライン作成委員会 ; 照井正, 秋山真志, 池田志斈ほか. 日本皮膚科学会膿疱性乾癬 (汎発型) 診療ガイドライン 2014年度版. 日皮会誌 2015 ; 125 : 2211-57.
2) 大槻マミ太郎, 五十嵐敦之, カンポス エドゥアルドほか. 乾癬治療薬としてのメトトレキサート-国内使用実態と安全対策. 日皮会誌 2019 ; 129 : 1317-28.
3) 日本皮膚科学会乾癬生物学的製剤検討委員会. 大槻マミ太郎, 佐伯秀久, 照井正ほか. 乾癬における生物学的製剤の使用ガイダンス (2019年版). 日皮会誌 2019 ; 129 : 1845-64.
4) Ikeda S, Takahashi H, Suga Y, et al. Therapeutic depletion of myeloid lineage leucocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J Am Acad Dermatol 2013 ; 68 : 609-17.
5) Kanekura T. Clinical and immunological effects of adsorptive myeloid lineage leucocyte apheresis in patients with immune disorders. J Dermatol 2018 ; 45 : 945-50.

6章 掌蹠膿疱症

P.318 掲載の参考文献
1) Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis : A nationwide study using the Japanese national claims database. BMJ Open 2015 ; 5 : e006450.
2) 平野宏文, 大久保ゆかり. レセプトデータからみたPPP患者の検討. PPPフロンティア 2018 ; 3 : 6-10.
3) 柳内充, 荻野武, 高原幹ほか. 掌蹠膿疱症家族内発生例のHLAタイピング. 耳鼻臨床 2001 ; 94 : 909-13.
4) Matsuoka Y, Okada N, Yoshikawa K. Familial cases of psoriasis vulgaris and pustulosis palmaris et plantaris. J Dermatol 1993 ; 20 : 308-10.
5) Akiyama M, Takeichi T, McGrath JA, et al. Autoinflammatory keratinization diseases : An emerging concept encompassing various inflammatory keratinization disorders of the skin. J Dermatol Sci 2018 ; 90 : 105-11.
6) Takahashi T, Fujimoto N, Kabuto M, et al. Mutation Analysis of IL36RN Gene in Japanese Patients With Palmoplantar Pustulosis. J Dermatol 2017 ; 44 : 80-3.
7) Tobita R, Egusa C, Maeda T, et al. A Novel CARD14 Variant, Homozygous c.526G > C (p.Asp176His), in an Adolescent Japanese Patient With Palmoplantar Pustulosis. Clin Exp Dermatol 2019 ; 44 : 694-6.
8) Mossner R, Frambach Y, Wilsmann-Theis D, et al. Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients. J Invest Dermatol 2015 ; 135 : 2538-41.
9) Akiyama T, Seishima M, Watanabe H, et al. The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections J Dermatol 1995 ; 22 : 930-4.
10) 橋本喜夫, 飯塚一. 旭川医科大学最近17年間の掌蹠膿疱症の統計-扁摘術の有効性の検討も含めて. 臨床皮膚科 2006 ; 60 : 633-7.
11) 藤城幹山, 坪井良治, 大久保ゆかり. 当科における過去3年間の掌蹠膿疱症111例の統計学的検討, 日皮会誌 2015 ; 125 : 1775-82.
12) 加瀬貴美, 肥田時征, 米田明弘ほか. 札幌医科大学附属病院皮膚科で経験した掌蹠膿疱症66例の統計学的検討. 日皮会誌 2012 ; 122 : 1375-80.
P.325 掲載の参考文献
1) Sonozaki H, Kawashima M, Hongo O, et al. Incidence of arthro-osteitis in patients with pustulosis palmaris et plantaris. Ann Rheum Dis 1981 ; 40 : 554-7.
2) Uehara M, Ofuji S. The morphogenesis of pustulosis palmaris et plantaris. Arch Dermatol 1974 ; 109 : 518-20.
3) Misiak-Galazka M, Wolska H, Rudnicka L. Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity? J Eur Acad Dermatol Venereol 2017 ; 31 : e342-3.
4) Yamamoto T. extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2009 ; 23 : 1227-32.
5) Hiraiwa T, Yamamoto T. Nail involvement associated with palmoplantar pustulosis. Int J Dermatol 2017 ; 56 : e26-43.
6) Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988 ; 6 : 109-12.
P.332 掲載の参考文献
1) Andrews GC, Machacek GF. Pustular bacterids of the hands and feet. Arch Derm Syphilol 1935 ; 32 (6) : 837-47.
2) Barbar HW. Acrodermatitis continua vel perstans and psoriasis pustulosa. Br J Dermatol 1930 ; 42 : 500.
3) Lever WF. Pustulosis palmaris et plantaris. In : Histopathology of the Skin. 4th edition, Lippincott ; 1967. pp.149-50.
4) 山本俊幸, 村上正基. Palmoplantar psoriasis について. PPPフロンティア 2017 ; 2 : 42-5.
5) Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol 2010 ; 130 : 2010-6.
6) Eriksson MO, Hagforsen E, Lundin IP, et al. Palmoplantar pustulosis : A clinical and immunohistological study. Br J Dermatol 1998 ; 138 : 390-8.
8) Skov L, Beurskens FJ, Zachariae CO, et al. IL-8 as antibody therapeutic target in inflammatory diseases : Reduction of clinical activity in palmoplantar pustulosis. J Immunol 2008 ; 181 : 669-79.
9) Murakami M, Kaneko T, Nakatsuji T, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS One 2014 ; 9 : e110677.
10) Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011 ; 20 : 845-7.
11) Xiaoling Y, Chao W, Wenming W, et al. Interleukin (IL) -8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. Clin Exp Dermatol 2019 ; 44 : 52-7.
12) Kaneko T, Murakami M, Kishibe M, et al. Over-expression of kallikrein related peptidases in palmoplantar pustulosis. J Dermatol Sci 2012 ; 67 : 73-6.
P.334 掲載の参考文献
1) 鈴木昌也. 遷延感作による皮疹発症の実験的研究-扁桃と掌蹠膿疱症. 日扁桃誌 1982 ; 21 : 228-38.
2) Hayashi Y, Kunimoto M, Kuki K, et al. Animal model of focal tonsillar infection : Human tonsillar lymphocytes induce skin lesion in SCID mice. Acta Otolaryngol (Stockh) 1996 ; 523 (Suppl) : 193-6.
3) Yamanaka N, Yamamoto Y, Kuki K. Engraftment of tonsillar mononuclear cells in human skin/SCID mouse chimera-validation of a novel xenogeneic transplantation model for autoimmune diseases. Microbiol Immunol 2001 ; 45 : 507-14.
4) 山本良一, 斎藤匡人, 九鬼清典ほか. 掌蹠膿疱症における扁桃の役割-SCIDマウスへの扁桃リンパ球および皮膚移植の試み. 耳鼻免疫アレルギー 1999 ; 17 : 86-7.
5) Hayashi M, Fujihara K, Beder LB, et al. Pathogenic role of tonsillar lymphocytes in associated with HSP60/65 in Pustulosis Palmaris et Plantaris. Auris Nasus Larynx 2009 ; 36 : 578-85.
P.337 掲載の参考文献
1) Nakayama H, Nogi N, Kasahara N, et al. Allergen control. An indispensable treatment for allergic contact dermatitis. Dermatol Clin 1990 ; 8 : 197-204.
2) 伊藤明子. 掌蹠膿疱症の今を知る. 掌蹠膿疱症と歯科金属アレルギー. PPPフロンティア 2017 ; 2 : 13-6.
3) Andrews GC. Machacek GF. Pustular bacteroids of the hands and feet. Arch Dermatol Syph 1935 ; 32 : 837-47.
4) Masui Y, Ito A, Akiba Y, et al. Dental metal allergy is not the main cause of palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2019 ; 33 (4) : e180-1.
5) 足立厚子, 堀川達也. 金属アレルギーに対するパッチテスト-全身型金属アレルギーの臨床症状, アレルゲンの特徴や生活・食事指導. Derma 2013 ; 200 : 37-44.
P.344 掲載の参考文献
1) Acharya A, Chan Y, Kheur S, et al. Salivary microbiome in non-oral disease : A summary of evidence and commentary. Arch Oral Biol 2017 ; 83 : 169-73.
2) Gupta VK, Paus S, Dutta C. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol 2017 ; 8 : 1162.
3) Kouno M, Nishiyama A, Minabe M, et al. Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal. J Dermatol 2017 ; 44 : 695-8.
4) Kouno M, Akiyama Y, Minabe M, et al. Dysbiosis of oral microbiota in palmoplantar pustulosis patients. J Dermatol Sci 2019 ; 93 : 67-9.
5) Watanabe H, Goto S, Mori H, et al. Comprehensive microbiome analysis of tonsillar crypts in IgA nephropathy. Nephrol Dial Transplant 2017 ; 32 : 2072-9.
P.351 掲載の参考文献
1) Kuczynski J, Lauber CL, Walters WA, et al. Experimental and analytical tools for studying the human microbiome. Nat Rev Genet 2011 ; 13 (1) : 47-58.
2) 黒木香奈. 掌蹠膿疱症とマイクロバイオーム. PPPフロンティア 2018 ; 3 : 42-5.
3) Grice EA, Kong HH, Conlan S, et al. Topographical and Temporal Diversity of the Human Skin Microbiome. Science 2009 ; 324 : 1190-2.
4) Grice EA. The skin microbiome : Potential for novel diagnostic and therapeutic approaches to cutaneous disease. Semin Cutan Med Surg 2014 ; 33 (2) : 98-103.
5) Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012 ; 22 : 850-9.
6) 後藤慶一. DNA塩基配列を用いたカビ・酵母の同定. モダンメディア 2009 ; 55 : 237-42.
7) 杉田隆, 高島昌子. 病原性酵母の分類と同定における最近の動向. Med Mycol J 2011 ; 52 : 107-15.
8) Findley K, Oh J, Yang J, et al. Topographic diversity of fungal and bacterial communities in human skin. Nature 2013 ; 498 : 367-70.
9) Sugita T, Zhang E, Tanaka T, et al. Recent advances in research on Malassezia microbiota in humans. Med Mycol J 2013 ; 54 : 39-44.
10) Ishibashi Y. Role of Malassezia colonization in cutaneous immune response. Jpn J Med Mycol 2009 ; 50 : 147-9.
11) Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol 2010 ; 130 : 2010-6.
12) Murakami M, Kaneko T, Nakatsuji T, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS One 2014 ; 9 : e110677.
13) Matsumoto Y, Harada K, Maeda T, et al. Molecular detection of fungal and bacterial DNA from pustules in patients with palmoplantar pustulosis : Special focus on Malassezia species. Clin Exp Dermatol 2020 ; 45 : 36-40.
14) Masuda-Kuroki K, Murakami M, Tokunaga N, et al. The microbiome of the "sterile" pustules in palmoplantar pustulosis. Exp Dermatol 2018 ; 27 : 1372-7.
P.357 掲載の参考文献
1) Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol 2010 ; 130 : 2010-6.
2) Masuda-Kuroki K, Murakami M, Kishibe M, et al. Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. J Dermatol 2019 ; 46 (5) : 399-408.
3) 阿部名美子, 斉藤万寿吉, 大久保ゆかり. 掌蹠膿疱症発症前に急性汎発性膿疱性細菌疹様皮疹を併発した症例. PPPフロンティア 2019 ; 3 : 63-6.
4) Murakami M, Muto J, Masuda-Kuroki K, et al. Pompholyx vesicles contain small clusters of cells with high levels of hyaluronate resembling the pustulovesicles of palmoplantar pustulosis. Br J Dermatol 2019 ; 181 : 1325-7.
P.360 掲載の参考文献
1) Uehara M, Ofuji S. The morphogenesis of pustulosis palmaris et plantaris. Arch Dermatol 1974 ; 109 : 518-20.
2) 藤澤大輔, 照井正. ダーモスコピー所見Visual Dermatology 2012 ; 11 : 1022-3.
3) Masuda-Kuroki K, Murakami M, Kishibe M, et al. Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. J Dermatol 2019 ; 46 : 399-408.
P.366 掲載の参考文献
1) Becher G, Jamieson L, Leman J. Palmoplantar pustulosis : A retrospective review of comorbid conditions. J Eur Acad Dermatol Venereol 2015 ; 29 : 1854-6.
2) Hiraiwa T, Yamamoto T. Comorbidities of Japanese patients with palmoplantar pustulosis : A report from a single center. Int J Dermatol 2018 ; 57 : e40-1.
3) Yamamoto T. Clinical characteristics of Japanese patients with palmoplantar pustulosis. Clin Drug Invest 2019 ; 39 : 241-52.
4) Yamamoto T, Hiraiwa T, Tobita R, et al. Characteristics of Japanese patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis : a multicenter study. Int J Dermatol 2020 ; 59 : 441-4.
5) Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis : A nationwide study using the Japanese national claims database. BMJ Open 2015 ; 5 : e006450.
6) Hiraiwa T, Yamamoto T. Bone scintigraphy analysis of 44 cases of pustulotic arthro-osteitis associated with palmoplantar pustulosis. J Dermatol 2019 ; 46 : e122-3.
7) Harabuchi Y, Takahara M. Pathogenic role of palatine tonsils in palmoplantar pustulosis : A review. J Dermatol 2019 ; 46 : 931-9.
8) Yamamoto T. Pustulotic arthro-osteitis associated with palmoplantar pustulosis. J Dermatol 2013 ; 40 : 857-63.
9) Rozin AP. Trends of SAPHO therapy : Should we be content? Curr Rev Rheumatol 2013 ; 9 : 28-33.
10) 山本俊幸. 掌蹠膿疱症性骨関節炎とSAPHO症候群-両者の考え方についてのアンケート調査. 日皮会誌 2016 ; 126 : 1915-21.
P.373 掲載の参考文献
1) Chamot AM, Benhamou CL, Kahn MF, et al. Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Rev Rhum Mal Osteoartic 1987 ; 54 : 187-96.
2) Giedion A, Holthusen W, Masel LF, et al. Subacute and chronic "symmetrical" osteomyelitis. Ann Radiol (Paris) 1972 ; 15 : 329-42.
3) Kohler H, Uehlinger E, Kutzner J, et al. Sternocostclavicular hyperostosis : Painful swelling of sternum, clavicules, and upper ribs. Report of two cases. Ann Intern Med 1977 ; 87 : 192-4.
4) Sonozaki H, Azuma A, Okai K, et al. Clinical features of 22 cases with "inter-sterno-costo-clavicular ossification". A new rheumatic syndrome. Arch Orthop Trauma Surg 1979 ; 95 : 13-22.
5) Sonozaki H, Kawashima M, Hongo O, et al. Incidence of artho-osteitis in patients with pustulosis palmaris et plantaris. Ann Rheum Dis 1981 ; 40 : 554-7.
7) Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988 ; 6 : 109-12.
8) Aljuhani F, Tournadre A, Tatar Z, et al. The SAPHO syndrome : A single-center study of 41 adult patients. J Rheumatol 2015 ; 42 : 329-34.
9) Rukavina I. SAPHO syndrome : A review. J Child Orthop 2015 ; 9 : 19-27.
10) Rozin AP. SAPHO syndrome : Is a range of pathogen-associated rheumatic diseases extended? Arthritis Res Ther 2009 ; 11 : 131.
11) Assmann G, Wagner AD, Monika M, et al. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome. Rheumatol Int 2010 ; 30 : 1273-6.
12) Berthelot JM, Corvec S, Hayem G. SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes. Joint Bone Spine 2018 ; 85 : 171-6.
13) Okuno H, Watanuki M, Kuwahara Y, et al. Clinical features and radiological findings of 67 patients with SAPHO syndrome. Mod Rheumatol 2018 ; 28 : 703-8.
14) Depasquale R, Kumar N, Lalam RK, et al. SAPHO : What radiologists should know. Clin Radiol 2012 ; 67 : 195-206.
15) Kahn MF. Proposed classification criteria of SAPHO syndrome. Proceedings of the Annual Meeting of the American College of Radioligy, Orlando, Florida. October 23-28, 2003.
16) Hayem G. SAPHO Syndrome. Rev Prat 2004 ; 54 : 1635-6.
P.375 掲載の参考文献
Roderick MR, Sen ES, Ramanan AV. Chronic recurrent multifocal osteomyelitis in children and adults : Current understanding and areas for development. Rheumatology (Oxford) 2018 ; 57 : 41-8.
Taddio A, Ferrara G, Insalaco A, et al. Dealing with Chronic Non-Bacterial Osteomyelitis : A practical approach. Pediatr Rheumatol Online J 2017 ; 15 : 87.
Hofmann SR, Kapplusch F, Mabert K, et al. The molecular pathophysiology of chronic non-bacterial osteomyelitis (CNO) : A systematic review. Mol Cell Pediatr 2017 ; 4 : 7.
Girschick H, Finetti M, Orlando F, et al. The multifaceted presentation of chronic recurrent multifocal osteomyelitis : A series of 486 cases from the Eurofever international registry. Rheumatology (Oxford) 2018 ; 57 ; 1203-11.
Wipff J, Costantino F, Lemelle I, et al. A large national cohort of French patients with chronic recurrent multifocal osteitis. Arthritis Rheumatol 2015 ; 67 : 1128-37.
P.377 掲載の参考文献
1) 藤城幹山, 坪井良治, 大久保ゆかり. 当科における過去3年間の掌蹠膿疱症111例の統計学的検討. 日皮会誌 2015 ; 125 : 1775-82.
2) Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis : A nationwide study using the Japanese national claims database. BMJ Open 2015 ; 5 : e006450.
3) Tobita R, Egusa C, Maeda T, et al. A novel CARD14 variant, homozygous c.526G > C (p.Asp176His), in an adolescent Japanese patient with palmoplantar pustulosis. Clin Exp Dermatol 2019 ; 44 : 694-6.
4) Akiyama M, Takeichi T, McGrath JA, et al. Autoinflammatory keratinization diseases. J Allergy Clin Immunol 2017 ; 140 : 1545-7.
5) Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 2012 ; 90 : 796-808.
P.384 掲載の参考文献
1) Andrews GC, Birkman FW, Kelly RJ. Recalcitrant pustular eruptions of the palms and soles. Arch Derm Syphilol 1934 ; 29 : 548-63.
2) 小林里実. 治療に難渋する病態への対応. (4) 掌蹠膿疱症の診断と治療. 皮膚臨床 2018 ; 60 (10) : 1539-44.
3) Hagforsen E, Michaelsson K, Lundgren E, et al. Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders : A case-control study. Acta Derm Venereol 2005 ; 85 : 225-32.
4) Masui Y, Ito A, Akiba Y, et al. Dental metal allergy is not the main cause of palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2019 ; 33 : e180-1.
5) 大久保ゆかり. 掌蹠膿疱症の治療法. PPPフロンティア 2016 ; 1 : 18-22.
6) Moutsopoulos NM, Madianos PN. Low-grade inflammation in chronic infectious diseases : Paradigm of periodontal infections. Ann NY Acad Sci 2006 ; 1088 : 251-64.
7) Takahara M, Hirata Y, Nagato T, et al. Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis : A retrospective subjective and objective quantitative analysis of 138 patients. J Dermatol 2018 ; 45 : 812-23.
8) Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis : A randomized clinical trial. JAMA Dermatol 2018 ; 154 : 309-16.
9) Yamamoto T, Fukuda K, Morita A, et al. Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52 : An exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2020 (Epub ahead of print).
P.390 掲載の参考文献
1) 藤城幹山, 坪井良治, 大久保ゆかり. 当科における過去3年間の掌蹠膿疱症111例の統計学的検討. 日皮会誌 2015 ; 125 : 1775-82.
2) Harabuchi Y, Takahara M. Pathogenic role of palatine tonsils in palmoplantar pustulosis : A review. J Dermatol 2019 ; 46 : 931-9.
3) 熊井琢美, 高原幹, 原渕保明. 扁桃を病巣とした皮膚・骨関節疾患の臨床と病態. リウマチ科 2018 ; 59 : 206-12.
4) Takahara M, Hirata Y, Nagato T, et al. Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis : A retrospective subjective and objective quantitative analysis of 138 patients. J Dermatol 2018 ; 45 : 812-23.
5) Hsueh WY, Hsu WC, Ko JY, et al. Postoperative hemorrhage following tonsillectomy in adults : Analysis of population-based inpatient cohort in Taiwan. Auris Nasus Larynx 2019 ; 46 : 397-406.
P.395 掲載の参考文献
1) Andrews GC, Machacek GF. Pustular bacterids of the hands and feet. Arch Derm Syphilol 1935 ; 32 : 837-47.
2) 栗田浩. 歯のう蝕症. 全国医学部附属病院歯科口腔外科科長会議 (監). 口の中がわかるビジュアル歯科口腔科学読本. クインテッセンス出版 ; 2017. pp.72-4.
3) 金村成智. 歯のう蝕症の治療法. 全国医学部附属病院歯科口腔外科科長会議 (監). 口の中がわかるビジュアル歯科口腔科学読本. クインテッセンス出版 ; 2017. pp.76-9.
4) 山本洋子, 橋本明彦, 冨樫きょう子ほか. 掌蹠膿疱症における歯性病巣治療の有効性について. 日皮会誌 2001 ; 111 : 821-6.
5) Kouno M, Nishiyama A, Minabe M, et al. Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal. J Dermatol 2017 ; 44 : 695-8.
6) 高橋愼一. 歯性病巣感染と掌蹠膿疱症. PPPフロンティア 2017 ; 2 : 46-50.
7) 日本歯周病学会 (編). 歯周病学用語集, 第3版. 医歯薬出版 ; 2019. p.56, 95.
8) Ishihara K, Ando T, Kosugi M, et al. Relationships between the onset of pustulosis palmaris et plantaris, periodontitis and bacterial heat shock proteins. Oral Microbiol Immunol 2000 ; 15 : 232-7.
9) Iwai C, Tsurusako S, Ohara Y, et al. Dental focal infection associated with skin diseases : A specific reference to α-hemolytic cocci. Jpn J Oncol Biol 2001 ; 43 : 310-5.
10) Kouno M, Akiyama Y, Minabe M, et al. Dysbiosis of oral microbiota in palmoplantar pustulosis patients. J Dermatol Sci 2019 ; 93 : 67-9.

7章 評価法 / 尺度

P.402 掲載の参考文献
1) Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978 ; 157 : 238-44.
2) Rich P, Scher RK. Nail Psoriasis Severity Index : A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003 ; 49 : 206-12.
3) Thaci D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis ; evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001 ; 203 : 153-6.
4) Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol 2008 ; 47 : 1019-23.
5) Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 1999 ; 26 : 210-5.
6) Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index : The impact of area should be increased. Br J Dermatol 2004 ; 151 : 381-7.
P.411 掲載の参考文献
1) Ohara Y, Kishimoto M, Takizawa N, et al. Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. J Rheumatol 2015 ; 42 (8) : 1439-42.
2) Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007 ; 34 : 1167-70.
3) van der Heijde D, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009 ; 68 : 1811-8.
4) Assessment of SpondyloArthritis international Society (ASAS). ASDAS calculator. https://www.asas-group.org/clinical-instruments/asdas-calculator/
5) Machado PM, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS) : Defining cut-off values for Disease Activity States and Improvement Scores. Ann Rheum Dis 2011 ; 70 : 47-53.
6) Machado PM, Landewe R, van der Heijde D ; Assessment of SpondyloArthritis International Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS) : 2018 Update of the Nomenclature for Disease Activity States. Ann Rheum Dis 2018 ; 77 : 1539-40.
7) Molto A, Gossec L, Meghnathi B, et al ; ASAS-FLARE study group. An Assessment in SpondyloArthritis International Society (ASAS) -endorsed Definition of Clinically Important Worsening in Axial Spondyloarthritis Based on ASDAS. Ann Rheum Dis 2018 ; 77 : 124-7.
8) Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis : The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 ; 21 : 2286-91.
9) Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis : the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 ; 21 : 2281-5.
10) Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994 ; 21 (9) : 1694-8.
11) Mease PJ, Van den Bosch F, Sieper J, et al. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. J Rheumatol 2017 ; 44 (5) : 599-608.
12) Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005 ; 32 (9) : 1745-50.
13) MiE : medical research. The Leed Dactylometer. https://www.mie-uk.com/dactylometer/dactylometermanual.pdf
14) Medicine Matters. Leeds Dactylitis Index. https://rheumatology.medicinematters.com/leeds-dactylitis-index/15811408
15) Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998 ; 51 : 1037-44.
16) Fukuhara S, Ware JE, Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998 ; 51 : 1045-53.
17) Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010 ; 69 (8) : 1441-7.
18) Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis : A proposed objective target for treatment. Ann Rheum Dis 2010 ; 69 (1) : 48-53.
P.416 掲載の参考文献
1) Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis : A randomized, double-blind, placebo-controlled study. Br J Dermatol 2001 ; 145 : 546-53.
2) 山本俊幸, 村上正基. Palmoplantar psoriasisについて. PPPフロンティア 2017 ; 2 : 42-5.
3) Andrews GC, Machacek GF. Pustular bacterids of the hands and feet. Arch Derm Syphilol 1935 ; 32 (6) : 837-47.
4) Barber HW. Acrodermatitis continua vel perstans and psoriasis pustulosa. Br J Dermatol 1930 ; 42 : 500-18.
5) Terui T, Kobayashi S, Okubo Y, et al. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis : A Randomized Clinical Trial. JAMA Dermatol 2018 ; 154 : 309-16.
6) Terui T, Kobayashi S, Okubo Y, et al. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis : A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2019 ; 155 : 1153-61.
P.423 掲載の参考文献
1) Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1994 ; 41 : 401-7.
2) 大久保ゆかり, 荒井佳恵, 藤原尚子ほか. Skindex-16/GHQ-28を用いた乾癬患者に対するQOL評価と治療満足度調査. 日皮会誌 2007 ; 117 : 2495-505.
3) 大久保ゆかり. 掌蹠膿疱症はいかに患者のQOLを低下させるか? J Visual Dermatol 2012 ; 11 : 1032-5.
4) Higaki Y, Kawamoto K, Kamo T, et al. The Japanese version of Skindex-16 : A brief quality-of-life measure for patients with skin diseases. J Dermatol 2002 ; 29 : 693-8.
5) Okubo Y, Natsume S, Usui K, et al. Low-dose,short-term ciclosporin (NeoralR) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol 2011 ; 38 : 465-72.
7) 福原俊一, 鈴鴨よしみ. DLQI日本語版とSkindex-29日本語版. アレルギーの臨床 2007 ; 358 : 23-7.
8) Takahashi N, Suzukamo Y, Nakamura M, Miyachi Y, Green J, Ohya Y, Finlay AY, Fukuhara S. Acne QOL Questionnaire Development Team. Japanese version of the Dermatology Life Quality Index : validity and reliability in patients with acne. Health and quality of life outcomes. 2006 ; 4 : 46.
9) Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis : A European consensus. Arch Dermatol Res 2011 ; 303 : 1-10.
10) Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI) : Further data. Dermatology 2015 ; 230 : 27-33.
11) 日本皮膚科学会乾癬生物学的製剤検討委員会 ; 大槻マミ太郎, 佐伯秀久, 照井正ほか. 乾癬における生物学的製剤の使用ガイダンス (2019年版). 日皮会誌 2019 ; 29 : 1845-64.
13) 福地修, 中川秀己, 長谷川友紀ほか. 乾癬特異的QOL指標Psoriasis Disability Index (PDI) 日本語版の開発と信頼性・妥当性の検討. 日皮会誌 2006 ; 116 : 1583-91.
14) 中川泰彬, 大坊郁夫. 日本版GHQ精神健康調査票-手引. 日本文化科学社 ; 1985.
15) Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980 ; 23 : 137-45
16) Wilsmann-Theis D, Jacobi A, Frambach Y, et al. Palmoplantar pustulosis-a cross-sectional analysis in Germany. Dermatol Online J 2017 ; 23 : pii : 13030/qt0h15613d.
17) Okubo Y, Tsuruta D, Tang AC, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol 2018 ; 32 : 606-14.

最近チェックした商品履歴

Loading...